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Abstract 
Spinocerebellar ataxia type 7 (SCA7) is an inherited neurodegenerative disease 
caused by the expansion of a CAG repeat within the ataxin-7 gene.  The South 
African SCA7 population has been shown to have arisen due to a founder effect, 
and a single nucleotide polymorphism (SNP) within ataxin-7 has been linked to the 
SCA7 mutation in all South African patients genotyped to date.  Recently, this SNP 
has been exploited in a potential allele-specific RNA interference (RNAi) based 
therapy, in order to knock down the expression of the mutant transcript in 
heterozygous patients.  Although this approach has been tested in an artificial cell-
based model of SCA7, focus has shifted towards testing the therapy in SCA7 
patient-derived transformed lymphoblast cell lines. 
 
The CAG repeat length and SNP genotype of each patient within the South African 
cohort was determined in order to fully characterise the cohort and establish the 
percentage of patients who may be eligible for the therapy.  Furthermore, a 
quantitative PCR (qPCR) assay was developed to specifically measure the expression 
of each allele of the SNP in patient- and control-derived transformed lymphoblast 
cell lines, in order to test the specificity of RNAi-based therapy.  Finally, qPCR was 
employed to measure the mRNA expression levels of heat shock proteins (Hsps) 27 
and 70 in patient- and control-derived cells, to identify phenotypic changes 
associated with the disease.    
 
The CAG repeat lengths of each patient were calculated, and it was found that 43% 
of the current patient population was heterozygous for the SNP, and therefore 
potentially eligible for the therapy.  Two allele-specific qPCR assays were designed 
and tested in patient- and control-derived cell lines.  Finally, expression 
experiments showed a significant increase in Hsp27 expression, and a significant 
decrease in Hsp70 expression in SCA7 patient-derived cells when compared to 
unaffected controls.  It is anticipated that these assays will be used in future studies 
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Chapter 1: Introduction 
Spinocerebellar ataxia type 7 (SCA7), an inherited neurodegenerative disease, is 
present at an unusually high frequency within the South African population when 
compared to the other inherited ataxias (Bryer et al., 2003).  Furthermore, there is 
evidence to suggest that the South African SCA7 population has arisen from a single 
founder population (Greenberg et al., 2006), providing researchers with a large, 
genetically homogenous population for study.  As a result of this phenomenon, 
recent work within the Division of Human Genetics has focussed on the 
development of a novel therapy for these individuals.  However, the need has 
arisen to determine the number of individuals who may be eligible for the therapy, 
and to develop an assay for testing the therapy in vitro in patient-derived cell lines. 
 
1.1 Spinocerebellar ataxias 
Spinocerebellar ataxias (SCAs), also known as autosomal dominant cerebellar 
ataxias (ADCAs), are a group of diseases characterised by cerebellar and spinal cord 
degeneration.  There are currently 30 genes known to be causative of SCA (Matilla-
Dueñas et al., 2010).  The SCAs have a broad range of neurological symptoms, 
including ataxia of gait, stance, and limbs, cerebellar dysarthria, oculomotor 
disturbances of cerebellar and supranuclear genesis, retinopathy, optic atrophy, 
spasticity, extrapyramidal movement disorders, peripheral neuropathy, sphincter 
disturbances, cognitive impairment, and epilepsy (Schols et al., 2004) .  A table of 
these symptoms, along with a brief description of each is presented below in Table 
1.  In the absence of comprehensive epidemiological data, the global prevalence of 
the SCAs has been estimated to be between 2 and 7 in 100 000 (Van de Warrenburg 
et al., 2002; Zhao et al., 2002; Duenas et al., 2006).  The SCAs are highly 
heterogeneous, with the age of onset, severity and rate of disease progression 
differing significantly between individuals (Bryer et al., 2003).  Clinical onset of the 
disease is usually between 30 and 50 years of age, although cases of onset in early 
childhood and after 60 years have been reported (Duenas et al., 2006).  The 
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although the rate of disease progression is often influenced by the nature of the 
pathogenic mutation. 
 
Table 1: Common neurological symptoms associated with the Spinocerebellar ataxias (adapted from Schöls et 
al., 2004) 
Symptom Description 
Ataxia Derived from the Greek word, "a taxis" meaning 
"without order” or “incoordination" 
Cerebellar dysarthria Caused by lesions in the cerebellum, resulting in 
jerky, uncoordinated movements of the speech 
musculature 
Oculomotor disturbances  Dysfunction of the oculomotor nerve, which 
controls most of the movement of the eye, the 
constriction of the pupil, and maintaining an open 
eyelid. 
Retinopathy Non-inflammatory damage to the retina of the eye 
Optic atrophy Deterioration of the optic nerve, which carries 
nerve impulses from the eye to the brain 
Spasticity Continuous contraction of specific muscles, 
resulting in difficulty in moving and talking 
Extrapyramidal movement 
disorders 
Symptoms including extreme restlessness, 
involuntary movements and uncontrollable speech 
Peripheral neuropathy Damage to the peripheral nervous system 
Sphincter disturbances Difficulty in controlling bodily sphincters 
Cognitive impairment Impaired brain function 
Epilepsy Recurring seizures 
 
A classification system based on the variable clinical presentations and 
neuropathologies of the ADCAs was first proposed by Harding in 1993, leading to 
the differentiation of the ataxias into three distinctive groups (Harding, 1993).  
ADCA type I contained the broadest range of clinical symptoms, and 
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cerebral cortex, optic nerve, pontomedullary systems, spinal tracts or peripheral 
nerves. Due to the broad range of symptoms, the majority of the SCAs are classified 
as ADCA type I.  ADCA type II is distinguishable by the presence of pigmented retinal 
degeneration, leading to pigmented retinopathy.  SCA type 7 is the only SCA to be 
classified within this group. Finally, ADCA type III is a pure cerebellar syndrome 
resulting from cerebellar degeneration, leading to the classification of SCAs type 5, 
6, 11, 14, 15, 16, 26 as ADCA type III disorders (Duenas et al., 2006). 
 
1.1.1 Polyglutamine repeat disorders 
Spinocerebellar ataxia type 7 (SCA7) is classified as a polyglutamine repeat disorder.  
In total, nine inherited neurodegenerative disorders are known to be caused by the 
expansion of an unstable trinucleotide CAG repeat within specific genes (Yamada et 
al., 2008).  These include six of the SCAs, (SCA 1, 2, 3, 6, 7 and 17), as well as 
Huntington’s disease (HD), dentatorubral-pallidoluysian atrophy, and spinal bulbar 
muscular atrophy (SBMA).  The CAG repeat size is highly variable, particularly in 
patients carrying repeats within the pathogenic range.  The translation of the CAG 
repeat leads to an expanded polyglutamine region within the corresponding 
protein.  Unaffected individuals generally carry alleles of between 4 and 18 repeats, 
whereas mutant alleles in SCA7 patients can range between 38 and 460 repeats 
(Michalik et al., 2004).  Individuals carrying alleles within the intermediate range 
(19-37) are typically unaffected, but have an increased risk of transmitting 
expanded alleles within the disease-causing range to offspring (Stevanin et al., 
1998).  It is generally accepted that the expanded polyglutamine tract changes the 
conformation of the protein, and leads to an altered function and interaction with 
other proteins (Orr and Zoghbi, 2007).  Consequently, the consensus amongst 
researchers is that pathogenesis is a result of a toxic gain-of-function acquired by 
the mutant protein.   
 
1.1.2 SCA7 
The earliest reports of Spinocerebellar ataxia type 7 (SCA7) date back to the 1930s 
and 1950s.  These describe patients with spinocerebellar degeneration and varying 
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(Froment et al., 1937; Bjork et al., 1956).  Figure 1 shows comparative images 
demonstrating atrophy of the cerebellum and pons evident in SCA7 patients.  The 
presence of pigmented retinal dystrophy in SCA7 patients has become a useful tool 
for distinguishing SCA7 from other cerebellar ataxias.  In 1996 the gene was 
mapped to the locus on chromosome 3p12-p13 (David et al., 1996).  Expanded 
polyglutamine repeats had already been identified as the pathogenic mutation 
underlying SCA1 and 3 (Orr et al., 1993; Kawaguchi et al., 1994).  These disorders, 
along with SCA7, showed strong anticipation in age of onset, particularly through 
paternal transmission, therefore it was thought that an expanded CAG repeat may 
have been underlying SCA7.  In 1997, David et al. identified the novel ataxin-7 gene 
by positional cloning, and established that SCA7 was associated with the expansion 
of a trinucleotide CAG repeat within the coding region of the gene.     
 
 
Figure 1:  Areas of pathological neuronal loss in SCA7 patients.  Image showing MRI scans of two individuals.  
An unaffected individual is shown on the left, and the right image showing a SCA7 patient.  The image on the 
right demonstrates marked atrophy of the pons and cerebellum.  Images obtained and adapted from 
http://hypothesisnow.files.wordpress.com/2010/03/mri_brain-nasa.jpg and Garden and La Spada (2007). 
 
1.1.3 The CAG repeat region & genetic anticipation 
An essential component of the diagnosis procedure for SCA7 is to determine the 
CAG repeat length of the individual.  This information can be used by clinicians for 
more effective management of the patient, since there is a distinct inverse 
relationship between CAG repeat length and the age of onset of symptoms 
(patients with larger repeats develop symptoms at an earlier age) (David et al., 
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estimate the age of onset and the rate of progression of the disease in individuals 
who are pre-symptomatic.  Furthermore, patients with SCA7 should be aware of the 
likelihood that any offspring inheriting the mutant allele will present with an earlier 
and more severe form of the disease if the repeat region expands further during 
transmission.  Genetic anticipation describes a phenomenon in genetic disorders 
when the symptoms become apparent at an earlier age as the disorder is passed on 
to successive generations.  Anticipation is common to a number of trinucleotide 
disorders, most likely due to the dynamic nature of the mutation.  It is also common 
for the severity of symptoms to increase as the disorder is transmitted.  A study by 
David et al. (1996) analysed 23 SCA7 parent-child couples, finding existence of 
noticeable anticipation, greater in paternal than maternal transmissions.  Gonadal 
mosaicism has been reported in the sperm of SCA7 patients, and increases of up to 
85 repeats have been observed in paternal transmissions (David et al., 1998). 
 
Most hypotheses for the proposed mechanism of CAG repeat expansion have been 
linked to the tendency of the expanded repeat regions to form unusual DNA 
structures, or to promote DNA slippage during replication and repair (Cleary and 
Pearson, 2005).  A recent study has shown that convergent bidirectional 
transcription can contribute to CAG repeat instability (Nakamori et al., 2011).  
However, many current reports propose that the genomic context of the repeat 
regulates instability.  Libby et al. (2003) used transgenic mice to show that various 
genomic modifications, such as deletion of the 3’ genomic region, could 
significantly stabilize intergenerational instability.  In 2008 the same group found 
that mutations within the CTCF protein binding site, downstream from the CAG 
expansion in the ataxin-7 gene, can promote repeat instability in germline and 
somatic tissues (Libby et al., 2008).  These results support the hypothesis that cis-
acting elements may predispose repeat regions to instability. 
 
The most common method of sizing the SCA7 repeat region is through polymerase 
chain reaction-mediated amplification of the repeat region and subsequent 
separation and size estimation through capillary electrophoresis (Sequeiros et al., 
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cycle sequencing may be employed.  Due to these different methods of size 
determination, it may be necessary in the future to develop a widely-accepted 
assay, along with published primer sequences, that is used by all laboratories to size 
the SCA7 repeat region (Sequeiros et al., 2010).  
 
1.1.4 Ataxin-7 protein 
When the gene underlying SCA7 was cloned, the normal function of the ataxin-7 
protein was unknown.  Northern blot analysis revealed a 7.5 kilobase transcript 
expressed in the heart, placenta, skeletal muscle, pancreas, brain, lung, liver, kidney 
and the central nervous system (David et al., 1997).  The 2727 base pair (bp) open 
reading frame encodes a 892 amino acid protein with several identifiable regions, 
including nuclear localization signals and a nuclear export signal, suggesting a  
potential shuttling function. 
 
Subsequent functional studies have indicated that ataxin-7 is a component of a 
mammalian transcription co-activator complex called STAGA (SPT3-TAF9-ADA-GCN5 
acetyltransferase) (Palhan et al., 2005), which functions to mediate interactions 
between transcriptional activators and the RNA polymerase II transcription 
complex.  STAGA and the closely related TATA-binding protein-free TAF containing 
complex (TFTC) promote histone acetylation, thereby mediating transcriptional 
activation (Garden and La Spada, 2007).  Although the exact function of ataxin-7 
within the STAGA/TFTC complex is still unknown, it has been shown that ataxin-7 
mediates an interaction between STAGA and the cone-rod homeobox  
transactivator of photoreceptor genes, linking the function of ataxin-7 with the 
retinal phenotype observed in SCA7 patients (Palhan et al., 2005).  Furthermore, 
polyglutamine-expanded ataxin-7 inhibits the histone acetyltransferase activity of 
STAGA, which is predicted to lead to retinal degeneration.  A recent study using a 
yeast two-hybrid screen has identified further interacting partners of the ataxin-7 
protein, highlighting the possibility that one or more unidentified partners may play 
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1.1.5 Pathogenesis 
Numerous hypotheses regarding the pathogenesis of polyglutamine disorders have 
been suggested in the literature.  These include (i) misfolding of the disease protein 
resulting in altered function; (ii) deleterious protein interactions engaged in by the 
mutant protein; (iii) formation of toxic oligomeric complexes; (iv) transcriptional 
dysregulation by the mutant protein; (v) mitochondrial dysfunction resulting in 
impaired bioenergetics and oxidative stress; (vi) impaired axonal transport; (vi) 
aberrant neuronal signalling; (vii) cellular protein homeostasis impairment; and (viii) 
RNA toxicity (summarized by Williams and Paulson, 2008).  However, it is most 
likely that combinations of one or more of these mechanisms result in the eventual 
phenotypes evident in the polyglutamine disorders.  There may be “non-specific” 
toxic effects of the mutant protein, or toxicity may be specific to the particular 
mutated protein, related to an alteration of its wild-type function. 
 
The SCA7 phenotypic feature that has been most commonly linked with 
pathogenesis and subsequent neurodegeneration is the presence of protein 
aggregates, or neuronal inclusions (NIs).  The NIs typically contain a range of 
proteins, including the mutant and wildtype polyglutamine protein, as well as 
components of the ubiquitin-proteosome system.  The aggregation of the expanded 
polyglutamine proteins, and their inclusion into NIs is a phenomenon common to all 
of the known polyglutamine disorders, but the exact role of the NIs in disease 
progression is still unknown.  Whilst initially it was suggested that the inclusions 
mediate neurodegeneration, recent groups have proposed that the inclusions are 
merely a consequence of  the abnormal protein aggregation, or that NIs may even 
play a protective role by sequestering the mutant proteins (Orr and Zoghbi, 2007; 
Arrasate et al., 2004).  For SCA7 in particular, it has been found that cerebellar 
Purkinje cells, a cell type severely affected by the disease, rarely display NIs.  In 
contrast, areas spared of degeneration (such as the cerebral cortex) have been 
found to exhibit NIs.  These findings suggest that the presence of NIs may not be 
causative of degeneration (Michalik et al., 2004).  However, in the absence of 
detailed studies into the exact mechanisms of aggregation, inclusion formation and 
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formation and pathogenesis.  For example, it is possible that NIs form earlier on in 
affected neuronal subtypes, or current imaging methods may not detect smaller NIs 
which may contribute significantly to pathogenesis.  Furthermore, there is some 
evidence in other polyglutamine diseases such as Huntington’s disease that 
implicates toxic intermediates formed during the aggregation process, rather than 
the inclusions themselves (Ross and Poirier, 2004). 
 
A characteristic of NI formation that is likely to contribute to degeneration is the 
recruitment of other cellular proteins into the nuclear inclusions.  The absence or 
reduced occurrence of these proteins in the cellular environment may interfere 
with their standard functioning, and later contribute to toxicity.  Whilst some 
recruited proteins are common to multiple polyglutamine diseases (such as 
particular molecular chaperones and ubiquitin), it is possible that future studies 
may reveal recruited proteins specific to the neuronal subtypes affected by the 
particular disease. 
 
It is still unknown how expanded ataxin-7 causes degeneration only in specific 
neuronal populations, in spite of its expression throughout the central nervous 
system and other non-neuronal organs.  Ataxin-7 has been shown to be expressed 
in numerous regions of the brain, and is not restricted to neuronal types affected by 
the disease (Lindenberg et al., 2000).  Another noteworthy feature is that the 
localization of the ataxin-7 protein has been found to vary between nuclear and 
cytoplasmic loci.  The protein localization is not specific to affected neuronal types.  
However, it has been suggested that the mutant protein may be more detrimental 
in cell types with high metabolic demands and protein turnover (Garden and La 
Spada, 2007).  It is possible that future comparative expression studies may reveal 
new ataxin-7 protein targets and interactants (such as STAGA-dependent 
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1.1.6 Treatment and therapy 
Since there is currently no known treatment for SCA7, clinical management is 
usually focussed on the alleviation of specific symptoms and management of the 
cognitive and psychiatric issues that may be associated with the condition.   
However, there are numerous studies exploring therapeutic strategies underway.  
One of the most challenging aspects of treating the polyglutamine disorders in 
general, is the nature of the mutation.  Since the mutation in polyglutamine repeat 
disorders is dynamic, and the repeat sizes of the expanded tract varies from patient 
to patient, it may be problematic  to directly target the repeat region in order to 
specifically silence the mutant transcript.  Since the specific function of the wild-
type protein is not always known (as in the case of SCA7), many strategies have 
opted to target the mutant transcript specifically, rather than completely abolishing 
expression of the transcript altogether.  However, in some cases, silencing of both 
the wild-type and mutant transcripts may be tolerated, as has been found in a rat 
model of SCA3 (Alves et al., 2010).  Because the mutation is shared across the 
polyglutamine disorders, it is likely that a therapeutic strategy for a particular 
disorder may be applicable to many, if not all, the polyglutamine disorders. 
 
The next problem that arises is how to specifically target the mutant transcript.  In a 
strategy adopted by Hu et al. (2009), antisense oligomers have been employed to 
target expanded CAG repeats preferentially.  It was found that this method can be 
used to specifically silence mutant htt (responsible for HD) and ataxin-3 protein 
expression in cultured cells.  Whilst this method may be beneficial to a number of 
the polyglutamine disorders, it is unlikely that it could be used for patients with 
shorter expanded repeats that are in the pathogenic range.   
 
Mouse studies can provide important clues towards the function of the wild-type 
protein, and can therefore direct therapeutic strategies.  For example, htt  knockout 
mice are embryonically lethal (Nasir et al., 1995), and therefore studies have 
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characterised SCA7 animal model, investigations into SCA7 therapies have adopted 
a similar approach.      
 
Another popular therapeutic strategy employs the use of allele-specific silencing by 
targeting a polymorphism specific to the mutant transcript.  Whilst this approach 
may be useful in smaller populations, it is unlikely that a single polymorphism will 
be present at a high enough frequency in a larger population to be beneficial to a 
large proportion of individuals.  In addition, the individuals need to be heterozygous 
for the polymorphism in order for the therapy to be applicable.  Therefore, it may 
be necessary to target multiple polymorphisms.  Pfister et al. (2009) have 
developed a panel of five small interfering RNAs, targeting 3 single nucleotide 
polymorphisms (SNPs), that they propose can be used to treat three-quarters of the 
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1.2 RNAi 
RNA interference (RNAi) describes a conserved regulatory mechanism employed by 
most eukaryotic cells to control gene activity (Kim and Rossi, 2008).  This 
phenomenon was first discovered in Caenorhabditis elegans, when it was noted 
that the introduction of double-stranded RNAs (dsRNAs) prompted the silencing of 
the complementary messenger RNA (mRNA) sequence (Fire et al., 1998).  Three 
years later it was shown that the same mechanism could be triggered in 
mammalian cells (Elbashir et al., 2001).  Another three years later, Phase I Clinical 
Trials on the first RNAi-based human therapeutics were launched.  According the 
the US National Institute of Health, there are currently at least five clinical trials 
based on potential RNAi therapies (www.clinicaltrials.gov).  Disorders targeted in 
these trials include cancer and AIDS. 
 
The mechanism of cellular silencing using RNAi can be separated into two main 
pathways, illustrated in Figure 2.  The first, transcriptional gene silencing, is 
mediated through mechanisms that are not well understood, but are likely to 
include chromatin modification (Grishok et al., 2005). The second, post-
transcriptional gene silencing can be divided into two pathways, whereby the target 
mRNA is either cleaved in a sequence-specific manner or translation is repressed 
and the mRNA is degraded. 
 
Long primary transcripts called primary-microRNAs (pri-miRNAs) act as the 
substrates for the endogenous RNAi pathway.  The expressed transcripts are 
processed into 60-70bp short hairpins, called precursor-microRNAs (pre-miRNAs), 
by the Drosha-DGCR8 microprocessor complex (Lee et al., 2003).  The pre-miRNAs 
are then transported from the nucleus to the cytoplasm by exportin 5 (XPO5) (Yi et 
al., 2003).  In the nucleus, the pre-miRNAs are cleaved by an RNaseIII endonuclease 
called Dicer into shorter fragments (~21-25 nucleotides long), termed microRNAs 
(miRNAs) (Zhang et al., 2004). These miRNAs are in turn recruited by a protein 
complex known as the RNA-induced silencing complex, or RISC.  Once loaded into 
RISC, the sense or “passenger” strand of the double-stranded miRNA is cleaved by 
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or “guide” strand binds to its complementary mRNA transcript. Perfectly 
complementary mRNAs are cleaved by the catalytic domain of AGO2, whilst the 
translation of imperfectly complementary mRNAs is repressed.  These mRNAs are 
then degraded in a non-sequence-specific manner by P bodies (Liu et al., 2005).  
Both mechanisms result in effective post-transcriptional gene silencing. 
 
   
Figure 2:  The mammalian RNAi pathway. (a) Primary microRNAs (Pri-miRNAs) are processed by Drosha and 
DiGeorge syndrome critical region 8 (DGCR8) into precursor miRNAs (Pre-miRNAs) and transported into the 
cytoplasm by exportin 5 (XPO5).  In the cytoplasm the pre-miRNA is bound by pre-RNA induced silencing 
complex (pre-RISC) containing Dicer, the catalytic core Argonaute 2 (AGO2), and accessory proteins HIV tar-
RNA-binding protein (TRBP) and activator of protein kinase PKR (PACT).  The guide sequence binds to 
complementary sequences in cellular mRNAs.  Perfect complementation leads to sequence-specific cleavage 
and mRNA degradation (left pathway), whilst incomplete complementation leads to translational inhibition 
accompanied by non sequence-specific degradation in P bodies.  (b) Artificially transcribed short hairpin RNAs 
(shRNAs) follow a similar pathway. (c) siRNAs complementary to promoter regions can trigger transcriptional 
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Pri-miRNAs do not act as the sole substrates for the RNAi pathway.  Long dsRNA 
structures, from a variety of sources (including viral RNAs, transgenes or 
transposons), are also processed by Dicer to yield shorter fragments, called short 
interfering RNAs (siRNAs).  These fragments progress through the pathway in the 
same fashion as miRNAs, resulting in post-transcriptional gene silencing. 
 
1.2.1 RNAi therapeutics 
In recent years, exploitation of the RNAi pathway has become a vital tool in 
molecular biology.  Because the sequence of the dsRNA substrate specifies which 
mRNA is translationally repressed, it is possible to introduce synthetic substrates in 
order to potently and specifically silence a gene of choice.  This may be for the 
purpose of silencing a disease-associated gene, or to elucidate the function of a 
gene by preventing its expression.  Diseases and disorders including viral infections, 
dominant genetic disorders and cancers may benefit from RNAi-based therapies in 
the future.   
 
Synthetic siRNAs can enter the RNAi pathway at a number of levels.  The first 
method of introduction is by direct transfection of the siRNA molecule into the 
target cell, whereafter the siRNA is taken up by RISC (Martinez et al., 2002).  In this 
manner siRNA introduction is able to produce transient transcriptional repression, 
since the intracellular concentrations of the siRNA molecules are diluted over time.  
The second method is by introduction of viral vectors containing Pol II or III 
promoters, which transcribe pri-miRNA mimics or short hairpin RNAs (shRNAs) 
(Amarzguioui et al., 2005).  These dsRNA molecules enter the pathway at a higher 
level than siRNAs, and are processed by Drosha and/or Dicer.  The obvious benefit 
is that the shRNAs can be expressed stably for a long period of time, and can be 
expressed in a tissue-specific manner if it is desired (Kim and Rossi, 2007). 
 
1.2.2 Challenges of RNAi 
Although the concept of using siRNAs to support genetic therapies is simple, some 
cautions and considerations must be taken into account.  Because the synthetic 
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same way as endogenous RNAi molecules, one of the main concerns when 
developing an RNAi-based therapy is that the molecules introduced may saturate 
the endogenous pathway.  Since the role of miRNAs is to “fine-tune” gene 
expression, introduction of foreign molecules into the pathway may perturb the 
natural system, resulting in undesirable effects.  A study where the gene encoding 
Dicer was disrupted resulted in embryonic lethality in mice, indicating that accurate 
performance of the RNAi pathway is essential for proper cell function (Bernstein et 
al., 2003).  Therefore, during the siRNA/shRNA design process, it is essential that 
potent effectors are chosen that are efficient at low doses, and that moderate, 
controllable vector systems are used for the expression of shRNAs (Aagaard and 
Rossi, 2007). 
 
Although eukaryotes use the RNAi system to modulate gene expression, the 
pathway is also used as a “molecular immune system”, to protect the host from 
dsRNA viral infections, transposons, retrotransposons, and retroviruses (Bagasra 
and Prilliman, 2004).  Therefore, the introduction of long dsRNA molecules results 
in an innate immune response.  This response leads to inhibition of protein 
synthesis, expression of anti-viral genes, and ultimately cell death (Gantier and 
Williams, 2007).  Therefore thorough testing using in vitro human primary cells and 
animal models should be completed before proceeding to clinical trials. 
 
Microarray studies have shown that cells treated with siRNAs show off-target 
silencing of a large number of non-targeted genes (Jackson et al., 2003).  Since a 
third of randomly-selected siRNAs have the ability to affect cell viability (suggesting 
that they can induce toxicity) (Fedorov et al., 2006), it is essential that siRNAs are 
thoroughly screened before being introduced into mammalian cells.  However, it 
may be possible to eliminate the toxic effect produced by siRNAs by the 
introduction of chemical modifications (Fedorov et al., 2006). 
 
One of the main challenges facing the design of effective RNAi-inducing molecules 
is that of how the effectors enter the cell.  As discussed above, siRNA/shRNA 
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usually requires the aid of packaging systems such as liposomes or nanoparticles, to 
allow the negatively-charged siRNA molecules to cross hydrophobic cellular 
membranes.  Chemical modifications are also required to prevent degradation by 
RNases (Kim and Rossi, 2007).  The siRNAs can either be delivered intravenously 
(so-called non-selective systemic delivery), or be directed towards their target cells 
via cell-specific surface receptors (selective systemic delivery).  In most cases it is 
preferential to have cell-specific delivery, to reduce dosage amount, and to prevent 
potential off-target effects in non-targeted cells. 
 
In order to treat chronic diseases it is necessary to stably express the shRNA 
effector targeting the gene of choice.  For these purposes, viral vectors are used as 
a mode of delivery.  Lentiviral vectors are able to stably tranduce both dividing and 
non-dividing cells.  The virus integrates into the host genome, allowing for stable 
expression of the shRNA effector, however, this phenomenon may lead to 
endogenous gene disruptions.  Vectors can also be derived from adenoviruses.  
These vectors do not integrate into the genome, and are therefore diluted over the 
course of successive cell divisions.  Adenoviral vectors are used where long-term 
RNAi delivery is not required, since repeated doses may initiate strong immune 
responses. 
 
1.3 Heat shock proteins 
The heat shock proteins (Hsps) are a set of proteins present in both eukaryotes and 
prokaryotes.  These proteins accumulate in the cell in response to external or 
intrinsic stimuli that induce stress within the cell, such as heat shock or oxidative 
stress.  A key role of the Hsps (also referred to as molecular chaperones) is to 
prevent or correct the misfolding of cellular proteins, thus preventing aggregation 
(Jakob et al., 1993).  The Hsps are classified into one of six families, based on their 
size (namely Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, and small heat shock proteins) 
(Jolly and Morimoto, 2000).  In each of the Hsp families, some members are 
constitutively expressed, whereas the expression of others is induced in response 
to stresses.  One of the hallmarks of many inherited neurodegenerative disorders, 
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proteins within inclusions in the cell.  Furthermore, the inclusions often include 
various proteins from the molecular chaperone and ubiquitin-proteasome 
pathways.  Therefore it is intuitive that dysregulation of the endogenous heat shock 
response within affected cells may contribute to pathogenesis.   
 
1.3.1 Heat shock proteins & SCA7 
Changes in Hsp expression have been found in a number of polyglutamine 
disorders.  Katsuno et al. (2005) found that administration of 
Geranylgeranylacetone, a nontoxic antiulcer drug, increased expression of Hsp70, 
90 and 105 in a cell model of SBMA.  As a result, cell death was inhibited, and 
accumulation of pathogenic androgen receptor protein (containing the expanded 
polyglutamine tract) was prevented (Katsuno et al., 2005).  In an HD mouse model, 
Hay et al. (2004) found that expression levels of Hsp70 were decreased to below 
40% of the endogenous levels.  Furthermore, aberrations in Hsp expression levels 
have been implicated in the pathogenesis of SCA7.  In a study by Merienne et al. 
(2003), expression levels of Hsp70 were reduced in the presence of polyglutamine 
expansions.  They went on to show that as a result, c-Jun N-terminal Kinase (JNK) 
phosphatases were inhibited, activating a pathway which may ultimately lead to 
cell death through JNK and c-Jun activation (Merienne et al., 2003).   
 
A study by Tsai et al. (2005) explored the potential relationship between SCA7 
pathogenesis and Hsps.   Hsps have been shown to suppress cellular toxicity and 
aggregate formation associated with polyglutamine expansion diseases (Cummings 
et al., 1998; Warrick et al., 1999).  Lymphoblasts isolated from SCA7 patients 
express the mutant ataxin-7 protein, providing researchers with a novel system to 
study the cellular effects of SCA7.  Tsai et al. used these cells to investigate any 
potential changes in Hsp expression in SCA7 patients.  Using lymphoblast cell lines 
from two SCA7 patients, the group investigated protein expression levels of Hsps 
27, 60, 70 and 90.  This group showed decreased endogenous expression of Hsp27 
and Hsp70 protein in SCA7 patient cell lines, whilst the expression of Hsps 60 and 
90 remained unaffected.  Semi-quantitative RT-PCR assays suggested that the 
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of Hsp27 mRNA were similar between cells with and without mutant ataxin-7, 
suggesting that the decreased expression of Hsp27 protein is not due to 
transcriptional dysfunction.  The authors hypothesized that the reduction of these 
heat shock proteins 27 and 70 in SCA7 cells may contribute to the accumulation of 
misfolded proteins and cellular stress associated with the condition (Tsai et al., 
2005).   
 
Additional reasons for reduced Hsp expression in polyglutamine disorders were 
proposed in a review by Huen et al. (2007).  Firstly, the Hsps may be recruited to 
the nuclear inclusions.  This has been demonstrated previously by groups such as 
Zander et al. (2001).  Alternatively, the ubiquitin-proteasome system may degrade 
the Hsps, but these hypotheses can not account for changes in mRNA expression 
levels.  Finally, the polyglutamine proteins may interfere with the transcription of 
the Hsps.  
 
1.4 Previous work 
1.4.1 SCA7 in South Africa 
Until 2003, very little data was available on the frequency of the SCAs in SA.  A ten-
year population-based study by Bryer et al. (2003) undertook to investigate the 
spectrum and prevalence of the SCAs in SA.  Of the total of 54 families investigated 
during this time, it was found that 12 of these (22.2%, all of Black African origin) 
exhibited the SCA7 genotype.  Most countries report a frequency of SCA7 of 
between 4.5 and 11.6%, apart from a Scandinavian population in Finland and 
Sweden with a higher reported frequency, suggested to be a result of a founder 
premutation (Jonasson et al., 2000).  Therefore the frequency of SCA7 reported in 
SA is believed to be one of the highest in the world.  In order to investigate 
potential reasons for the skewed incidence in SA, a haplotype study was 
undertaken in order assess the evidence for a founder effect in South African SCA7 
families.  A founder effect may be used to explain a loss of genetic variation (or an 
increased prevalence of a mutation) in a population if the population was 
established by a small group of “founder” individuals.  Furthermore, since the 
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alleles at specific genetic loci.  Alleles at multiple loci which are transmitted 
together on the same chromosome are referred to as a haplotype.  In the South 
African SCA7 population, a SNP and four microsatellite markers in a 5.21 
centimorgan region flanking the SCA7 gene were genotyped in five extended 
families.  It was found that affected individuals shared alleles at three loci flanking 
the mutation, and the allele frequencies were higher in the SCA7 patient population 
than the unaffected population (Greenberg et al., 2006).  These results are 
suggestive of a founder effect in the South African SCA7 Black African population.  
For the purposes of this study, it is important to note that the genotyped SNP was 
found to be linked to the SCA7 mutation, and more than 50% of the SCA7 patients 
had an “A” allele associated with the mutation, and a “G” allele associated with the 
wild-type ataxin-7 transcript.   
 
Previous work within the Division of Human Genetics at the University of Cape 
Town (UCT) has aimed at exploiting the endogenous RNAi pathway to develop a 
potential therapy for South African SCA7 patients.  One of the central issues facing 
developers of potential therapies for the polyglutamine disorders is that of how to 
specifically target the mutant transcript.  Although the function of the ataxin-7 
protein has not been well characterised, it is likely that the wild-type allele is 
necessary for normal cellular function.  It has been shown that antisense 
oligonucleotides are able to distinguish between mutant and wild-type alleles based 
on repeat length (Hu et al., 2009), however, other genes containing CAG repeat 
regions may be targeted in a non-specific manner.  Therefore, rather than targeting 
both ataxin-7 transcripts, or the expanded CAG repeat in the mutant allele, our 
group has exploited a SNP linked to the SCA7 mutation in our South African cohort 
to develop a potential RNAi-based therapy.  Using a similar SNP-targeting approach, 
Alves et al. (2008) have demonstrated allele-specific silencing of the mutant ataxin-
3 transcript in a rat model of SCA3.  Using this rat model, they were able to show 
that an shRNA effector designed to target a SNP within the mutant ataxin-3 CAG 
tract was able to decrease mutant ataxin-3 protein production, and 
neuropathological symptoms associated with SCA3.  However, the same group has 
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pathology in a SCA3 rat model (Alves et al., 2010), suggesting that total silencing of 
the ataxin-3 gene may be tolerated in vivo. 
 
For a previous study on the South African SCA7 cohort, multiple shRNAs 
(incorporating the SNP of interest (rs377 4729) at different positions) were 
screened to test for effective silencing of the mutant ataxin-7 transcript.  In order 
to achieve this, a SCA7 cell-based disease model was created by transfecting 
expression plasmids containing full-length constructs of wild-type or mutant ataxin-
7 cDNA, fused to eGFP or dsRED reporter targets, into HEK293 cells.  Quantification 
of fluorescence allowed for measuring of expression levels of the two transcripts 
after shRNA transfection.  Using this method, an shRNA effector capable of 
silencing the mutant transcript by more than 90% was identified (Scholefield PhD 
thesis, 2008; Scholefield et al., 2009).  It was also shown that transfection of the 
shRNA molecule resulted in decreased numbers of cells with intracellular 
aggregates, which are commonly associated with disease pathogenesis.   
 
Figure 3 illustrates the method developed by Scholefield et al. (2009) for effective 
silencing of the ataxin-7 mutant transcript.  In the South African cohort, patients 
with an expanded CAG repeat have an A allele at the SNP locus rs 377 4729.  Once 
the mutant transcript is transcribed, a mutant polyglutamine protein is produced, 
which leads to downstream pathogenic events, and the resultant SCA7 phenotype.  
The RNAi effector has been designed to target the A allele, thereby preventing the 
translation of the mutant transcript, resulting in no production of the mutant 
protein.  If the patient is heterozygous at the SNP position, the wild-type transcript 
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Figure 3: The method developed by Scholefield et al. (2009) for effective silencing of the ataxin-7 mutant 
transcript.  (A) In SCA7 patients the translation of the mutant ataxin-7 transcript (containing an expanded 
CAG repeat) leads to the production of mutant protein, whilst the wild-type transcript is translated to 
produce normal ataxin-7 protein.  In the South African cohort, the expanded CAG repeat is linked to the A 
allele of a downstream SNP (rs 377 4729).  (B) In heterozygous patients, the designed RNAi effector 
selectively targes the A allele of the SNP (linked to the expanded repeat), enabling the production of wild-
type ataxin-7 protein, but reducing the production of mutant protein.  
Whilst the RNAi effectors have been shown to be effective in an artificial cell-based 
model, the next step in the development of the therapy would be to test the 
therapy in patient-derived cells.  These cells express the mutant and wild-type 
ataxin-7 transcripts endogenously, rather than from a vector.  However, since the 
endogenous proteins are not fluorescently tagged (and therefore not detectable 
using microscopy), an alternative method must be developed to measure the 
expression of these transcripts and/or proteins in patient-derived cells. 
 
1.5 Problem identification 
The efficacy of the RNAi-based therapy described above was tested by measuring 
the levels of fluorescently-tagged mutant and wild-type ataxin-7 transcripts.  This 
was achieved by transfecting HEK293 cells with expression plasmids containing the 
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CytoMegalovirus promoter.  Although these findings strongly suggested that the 
identified shRNA effector could successfully distinguish between alleles, and reduce 
expression of the mutant transcript, it has become necessary to measure the effect 
of the shRNA molecule on expression levels of endogenous wild-type and mutant 
ataxin-7.  Since the SNP rs 377 4729 has been shown to be linked to the pathogenic 
SCA7 mutation within the South African patient cohort, the SNP can be used in 
allele-specific assays to measure the expression of each transcript in heterozygous 
samples.  Allele-specific expression can be measured via conventional PCR and real-
time quantitative PCR methods.  The PCR primers can be designed to incorporate 
the SNP at the 3’ end, to allow for efficient extension of matched primer-template 
duplexes, and little or no extension of mismatched duplexes (Kwok et al., 1994).  
Alternatively, Taqman probes could be designed to hybridize specifically to target 
sequences containing each allele of the SNP (Livak, 1999).  Each probe is labelled 
with a different fluorogenic tag, so each allele can be measured quantitatively 
within a single assay.       
 
Furthermore, it is necessary to identify and measure additional phenotypic markers 
(besides alleviation of aggregate formation) associated with the SCA7 phenotype in 
patient-derived cells, so that these markers may be measured post knock-down of 
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1.6 Goal of the current study 
The goal of this study was to characterise the current South African SCA7 cohort, in 
terms of determining patient CAG repeat lengths and SNP (rs 377 4729) genotypes, 
in order to establish who may be eligible for the RNAi-based therapy.  Transformed 
lymphoblast cell lines from a subset of these patients were then used to develop an 
assay for testing the efficacy of the proposed RNAi-based therapy. Furthermore, we 
aimed to develop a method for measuring Hsp27 and 70 mRNA expression levels in 
patient lymphoblasts, in order to validate previous studies showing reduced 
expression levels of these proteins in SCA7 patient cells.  This assay may give a 
further phenotypic measure of the efficacy of the therapy, if Hsp expression levels 
are restored after administration.  The implications of this study may ultimately 
include two useful assays for pre-testing the efficacy of the therapy in vitro in cells 
isolated from patient whole blood samples, before offering the treatment in vivo. 
 
1.6.1 Objectives 
A. To identify all SCA7 patients in the Division of Human Genetics database (up 
until the end of 2010) and determine their CAG repeat size and SNP 
genotype. 
B. To develop a quantitative assay to measure the levels of mutant and wild-
type ataxin-7 in SCA7 patient-derived transformed lymphoblasts. 
C. To develop a quantitative assay to measure mRNA levels of heat shock 
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Chapter 2: Materials & Methods 
 
2.1 Preparation of samples 
2.1.1 Database query and cohort selection 
The individuals included in this study were selected from the neurodegenerative 
disorder biological material repository and database in the Division of Human 
Genetics, UCT (REC/REF 229/2010).  The database contains information on South 
African families affected with or predisposed to the Spinocerebellar ataxias (SCAs).  
This information includes the results of clinical diagnostic tests and molecular 
genetic tests of potential SCA patients from throughout SA referred for genetic 
testing to the National Health Laboratory Services (NHLS) diagnostic laboratory at 
Groote Schuur Hospital.  Patient information and samples were collected according 
to the World Medical Association Declaration of Helsinki (2008).  The declaration 
outlines ethical principles for medical research involving human subjects.  Ethical 
approval for the study was provided by the Research Ethics Committee of the 
University of Cape Town (REC REF 228/2009). 
 
2.1.2 DNA isolation & integrity determination 
The Puregene® Genomic DNA Purification Kit (Gentra Systems, USA) was used to 
isolate genomic DNA from peripheral blood lymphocytes in 300 microlitres (µl) of 
whole blood.  The DNA isolation was routinely undertaken by a technologist within 
the Division of Human Genetics.  Firstly, cells were lysed with an anionic detergent 
in the presence of a DNA stabilizer.  The detergent facilitates lysis by disrupting cell 
membrane protein conformation, and the stabilizer prevents DNA degradation by 
limiting the activity of DNases.  Contaminating proteins were removed by salt 
precipitation, and resulting DNA was recovered by ethanol precipitation and 
subsequent re-suspension in a hydration solution.  The full protocol is listed in 
Appendix A.  One sample was placed in short term storage at -20 degrees 
Centigrade (°C), while the other sample was placed in long term storage at -80°C.  
The details of the location of each sample are recorded in paper-based and 
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Each of the DNA samples isolated from patient peripheral blood lymphocytes were 
retrieved from the appropriate storage locations.  The quality of the DNA samples 
were determined by analysing the concentration of the stock samples using the 
NanoDrop ND-1000 Spectrophotometer and NanoDrop 1000 software (NanoDrop 
Technologies, USA).   
 
The DNA stock solutions were diluted in sterile distilled water to working 
concentrations of 100ng/μl to be used in further investigations.  The working stock 
solutions were stored at -20°C for the duration of the research project.  The 
integrity of the diluted DNA solutions was determined by loading 200ng of the 
diluted DNA with 5μl loading dye (Appendix A) into the wells of a 1% weight per 
volume (w/v) agarose gel (Hispanger, Spain) (Appendix A).  The DNA was 
electrophoresed for 30 minutes at 160 volts (V).  SYBR gold nucleic acid staining was 
used (described in section 2.3.3.1), and DNA fragments were visualised under ultra-
violet (UV) light with the UVIPro UVIGold transilluminator (UVItec Limited, UK). 
 
2.2 Amplification of DNA by PCR 
2.2.1 PCR 
The polymerase chain reaction (PCR) is a method used for in vitro DNA amplification 
(Mullis and Faloona, 1987).  Single copy genomic sequences can be amplified by a 
factor of up to ten million with high specificity.  The process involves the addition of 
two oligonucleotide primers that flank the specific DNA sequence to be amplified.  
These hybridize to the template DNA strand to enable DNA synthesis by a heat 
stable DNA polymerase (called Taq polymerase, isolated from the thermo stable 
bacterium Thermus aquaticus).  Amplification of the DNA fragment is achieved 
through repeated cycles of heat denaturation of the double strand, annealing of the 
primers to their complementary sequences on the target DNA strand, and 
extension of these primers by DNA polymerase in the presence of deoxynucleotide 
triphosphates (dNTPs) (Saiki et al., 1988). 
 
All PCR reaction volumes were made up to a final volume of 25μl.  A standard PCR 
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(forward and reverse), 200μM of each deoxyribonucleotide triphosphate (dNTP) 
(Bioline, UK), 0.1 unit (U) GoTaq DNA Polymerase (Promega, USA), 1x Colorless 
GoTaq Reaction Buffer (ph 8.5, 1.5mM MgCl2) (Promega, USA) and distilled water 
made up to the final reaction volume.   
 
The standard cycling conditions for each PCR reaction included an initial 
denaturation step at 95°C for five minutes.  This was followed by 30 to 40 
amplification cycles, consisting of cycles of 95°C for 30 seconds to denature the 
double-stranded DNA, 30 seconds at a variable annealing temperature (specific to 
each primer pair) and 40 seconds at 72°C.  These cycles were followed by a final 
elongation step at 72°C for seven minutes.  All PCR reactions were performed on 
the MultiGene Gradient Thermal Cycler (Labnet International, USA), unless stated 
otherwise. 
 
Unless otherwise stated, all PCR and quantitative PCR primer sequences, reaction 
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2.3 Section A:  Determination of CAG repeat size in SCA7 patients 
Since 1997, for diagnostic and research purposes, the CAG repeat sizes of the SCA7 
patients in the Division of Human Genetics database had been determined.  
However, these studies had been performed by more than one individual, and at 
least two different methods of repeat sizing had been used.  Therefore, to obtain a 
consensus on the number of CAG repeats in each SCA7 patient, the following 
method was used on all samples for which genomic DNA was available. 
 
2.3.1 Gene information 
All genetic information (such as genomic DNA sequences and mRNA sequences) for 
the genes studied was obtained from the National Center for Biology Information 
(NCBI, http://www.ncbi.nlm.nih.gov/) and Ensembl (http://www.ensembl.org/ ) 
web-based gene browsers.  
 
2.3.2 Primer design & PCR optimization 
A PCR primer pair was previously designed for this research study by Ms F Baine 
(Division of Human Genetics, UCT) to lank the CAG repeat sequence within exon 3 
of the ataxin-7 transcript (NM_000333.3).  The primer sequences were submitted 
to the Oligo Calculator programme (http://www.cnr .berkeley.edu/~zimmer/oligo 
TMcalc.html) to obtain the length, melting temperature (Tm), %GC content, 
molecular weight and optical density reading at one picoMolar (pM). 
 
Primers were also submitted to the IDT OligoAnalyzer web-based tool 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) to 
determine potential self-complementarity, homodimer formation and heterodimer 
formation.  The designed primers were synthesized by the Department of 
Molecular and Cellular Biology, UCT.  They were diluted in distilled water to working 
concentrations of 20µM in a final volume of 200µl and stored at 4°C.  All primer 
sequences are given in Appendix B. 
 
In order to determine the optimal conditions for the PCR reaction, a number of 
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executed to establish the optimal annealing temperature for the reaction.  This 
assay used standard cycling conditions, but varied the annealing temperature by 
approximately 1°C across twelve PCR reactions.  Control DNA isolated from an 
individual with no known disease-causing mutations was used for all optimization 
assays. 
 
Should a temperature gradient not produce optimal results, it may be necessary to 
change additional parameters in the PCR reaction.  The following step in the 
optimization procedure for this particular PCR reaction was to utilize a PCR 
optimization kit (Roche, Switzerland).  Firstly, 16 PCR reactions were prepared using 
buffers of varying pH values and magnesium chloride (MgCl2) concentrations.  
Magnesium ions act as cofactors in the PCR reaction, and thus it is necessary to 
determine the optimal concentration in order to increase the specificity of the PCR 
reaction. 
 
In cases where a magnesium gradient did not provide results with sufficient 
specificity, a dimethylsulfoxide (DMSO) PCR gradient was performed in the same 
manner.  DMSO has been reported to reduce unspecific priming (Pomp and 
Medrano, 1991).  Since the CAG region which was targeted for amplification had a 
high GC content, it was decided to utilize an annealing time shorter than the 
standard 30 seconds used in a PCR reaction.  Mamedov et al. (2008) found that the 
optimal anneali g times for GC-rich regions lie between three and six seconds. 
 
The final step in the optimization process was to utilize FailSafe Premix buffer J 
(EPICENTRE Biotechnologies, USA) in the PCR reaction mix.  The buffer contains 
reagents such as magnesium and betaine to increase the specificity of the PCR 
amplification.  The PCR primer sequences, along with the PCR reaction composition 
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2.3.3 PCR product detection 
2.3.3.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to detect the amplified PCR products.  
Agarose gels were prepared using Agarose D-1 LE (Hispanger, Spain) and 1x tris 
borate EDTA Buffer (TBE) (Appendix A).  1x TBE buffer was also used as the 
electrophoretic medium.  All agarose gels prepared were 2 or 3% (w/v), unless 
otherwise stated. 
 
The PCR fragments were visualised using SYBR Gold nucleic acid staining (Molecular 
Probes Invitogen, USA).  SYBR Gold binds to double-stranded DNA and is detectable 
under UV light.  SYBR Gold loading buffer was prepared by adding 2µl SYBR Gold 
stock solution (10 000X solution) to 1ml of 1x loading dye (Appendix A).  Three 
microlitres of this solution was added to 5µl of the PCR product before 
electrophoresis.  In all cases the GeneRuler 100bp DNA Ladder Plus (Fermentas, 
Canada) was electrophoresed alongside PCR products to allow for approximate size 
determination of the products (Appendix A).  Electrophoresis was performed at 160 
V for approximately 40 minutes.  PCR products were visualised on the agarose gel 
under UV light using the UVIPro UVIGold transilluminator (UVItec Limited, UK).  The 
UVIpro (version 12.3) software was used to capture and edit images.    
 
2.3.3.2 Genotyping 
The ABI Prism 3100 Genetic Analyzer (Applied Biosystems, USA) was used for 
accurate size detection of the PCR products.  The automated fluorescence-based 
capillary electrophoresis system allowed for more sensitive sizing than conventional 
agarose gel electrophoresis methods.  One microlitre of each PCR product was 
mixed with 0.4µl GeneScan 500 ROX Size standard (Applied Biosystems, UK) and 8µl  
Hi-Di Formamide (Applied Biosystems, UK).  The resulting solution was added to the 
wells of a 96-well microtitre plate and denatured at 95°C for 5 minutes in a Hybaid 
Touchdown thermocycler (Hybaid Limited, UK), followed by snap freezing on ice.  
Following electrophoresis and detection, data collection was performed by the ABI 
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Biosystems).  The resulting raw data files were analysed to provide PCR product 
sizing using the GeneMapper software (Applied Biosystems, UK). 
 
2.3.4 Calculation of CAG repeat length 
The size of each PCR product was determined using the GeneMapper software, as 
described above.  The primer pair used in the PCR reaction was designed to flank 
the CAG repeat region, such that the size of the PCR product (excluding the repeat 
region) was 266 base pairs.  Therefore, to provide an approximation of the number 
of repeats within a PCR product, 266 was subtracted from the PCR product size, and 
the resulting figure was divided by 3 (because the repeat is a trinucleotide), as 
follows: 
 
                  
                      
 
      [1] 
 
A study by Dorschner et al. (2002) aimed to develop a multiplex PCR reaction to 
determine the CAG trinucleotide repeat lengths of SCA1, 2, 3, 6 and 7.  During 
capillary electrophoresis of the SCA amplicons, they found that the fragments 
migrated faster than predicted, leading to an underestimation of repeat size 
compared to results obtained from polyacrylamide gel electrophoresis (PAGE).  
Therefore a size-corr ction formula was calculated to determine the accurate 
number of CAG repeats.  The SCA7 formula [2] developed by this group was used to 
calculate the accurate repeat size of the individuals used in this project. 
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2.4 Section B: Determination of SNP genotype (rs 377 4729) in SCA7 
patients 
Not all patients stored within the database had previously been genotyped for SNP 
rs 377 4729.  Since this would be the SNP targeted by the RNAi-based therapy, this 
information could be utilized to determine whether patients could be eligible for 
the therapy, and to determine the scope of potential application of the therapy 
within the group of patients.  Therefore the SNP was genotyped in all samples that 
had not previously been genotyped. 
 
2.4.1 Primer design & PCR optimization 
Primers previously designed to flank the region of the SNP of interest were 
obtained from the primer database within the Division of Human Genetics, UCT 
(Greenberg et al., 2006).  A temperature gradient PCR was performed as described 
previously to determine the optimal annealing temperature for the reaction.  The 
primer sequences, reaction components and cycling conditions are listed in 
Appendix B and C. 
 
2.4.2 Restriction enzyme digestion 
Restriction enzyme digestion was used to determine the SNP genotype for each 
individual.  Restriction endonucleases are able to cleave double-stranded DNA at a 
nucleotide sequence specific to each enzyme, termed a restriction site.  Because 
the SNP of interest involved a GA nucleotide change, the restriction enzyme Hsp92II 
(Promega, UK) was chosen due to its recognition sequence of CATG↑.  Therefore it 
would preferentially cleave a DNA sequence containing an A allele at the position of 
interest, whilst leaving a sequence containing a G allele intact.  The sequence of the 
PCR product, along with the cleavage sites are presented in Figure 4.  The 
restriction digest reaction components are given in Table 2.  PCR products were 
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Figure 4:  Sequence of the 248 base pair SCA7 SNP PCR fragment.  The sequence is shown from 5’ to 3’.  The 
position of the A/G SNP is shown by R.  Hsp92II cleavage sites are underlined. 
 
Table 2: Hsp92II restriction digestion reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final concentration 
dH20 10  
Buffer K (Promega, UK) (10x) 2 1x 
Hsp92II (Promega, UK) (10U/µl) 1 0.5U/µl 
PCR product 7  
Total 20  
 
 
2.4.3 Product detection 
The expected fragment sizes following restriction enzyme digestion for each of the 
three genotypes are presented in Table 3.  Because some fragments differed in size 
by only 10 bases, it was necessary to resolve the fragments on a 6% polyacrylamide 
gel (Appendix A).  PCR fragments were visualised using silver nitrate staining 
(Appendix A). 
 
Table 3: SCA7 SNP genotypes & expected fragment sizes following Hsp92II digestion 
Genotype Fragment sizes (bp) 
Uncut 248 
GG 168, 80 
GA 168, 153, 80, 15 
AA 153, 80, 15 
 
2.4.4 Validation of genotype by direct cycle sequencing 
In some instances, direct cycle sequencing was employed to validate the genotype 
obtained from restriction enzyme digestion, or as an alternative means of 
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was developed by Sanger et al. (Sanger et al., 1977).  Cycle sequencing follows the 
same principle as PCR, but with fluorescently-labelled dideoxynucleotides 
incorporated into the reaction mix.  The incorporation of these nucleotides into the 
sequence results in sequence termination, since they lack a 3’ hydroxyl group.  Each 
of the four bases is labelled with a different coloured dye.  The products are 
separated on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, USA), which 
separates the fragments according to size, and reads the dye incorporated at the 3’ 
end of each fragment.  Finally, the sequence of the PCR product is constructed from 
this data. 
 
To carry out cycle sequencing, a PCR reaction designed to amplify the region of 
choice was completed as described previously (prior to restriction enzyme 
digestion), and PCR products were electrophoresed on an agarose gel.  Thereafter, 
the cycle sequencing reaction was prepared as below in Table 4, using reagents 
from the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, UK).  
Cycling conditions are given in Table 5. 
 
Table 4: Cycle sequencing reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
PCR product 3-8  
Forward or revers  primer (20µM) 0.5 0.5µM 
Terminator mix (Applied Biosystems) 2  
Dilution buffer (Applied Biosystems)(5x) 4 1x 
dH2O Up to 20µl  
Total 20  
 
Table 5: Cycling conditions for cycle sequencing 
Cycle number Temperature (°C) Time Number of cycles 
1 95 5 minutes 1 
2 96 30 seconds  
                          30  50 15 seconds 
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After the cycle sequencing reaction, samples were subjected to an ethanol 
precipitation clean-up reaction.  Samples were transferred to 1.5ml tubes, 
whereafter 2µl of Sodium Acetate (NaAc) (3M, pH 4.5) and 50µl of 100% Ethanol 
was added.  Samples were then incubated at -20°C overnight.  After incubation, 
samples were centrifuged for 10 minutes at 10 000 revolutions per minute (rpm) in 
then Eppendorf MiniSpin microcentrifuge (rotor F45-12-11).  The supernatant was 
discarded, and 30µl of 70% ethanol was added, followed by an additional 
centrifugation step at 10 000rpm for 10 minutes.  The supernatant was discarded, 
and samples were air-dried.  Thereafter, samples were re-suspended in 10µl dH2O 
and subjected to capillary electrophoresis on the ABI Prism 3100 Genetic Analyzer 
(Applied Biosystems, USA).  Results were analysed using the BioEdit Sequence 
Alignment Editor (Hall, 1999).  Within BioEdit, the ClustalW multiple sequence 
alignment program was used to align sequences from test samples to the NCBI 
reference sequence (NG_008227.1), in order to identify the position and genotype 
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2.5 Section C:  Development of a quantitative assay to measure levels 
of wild-type and mutant ataxin-7 
The aim of objective B of the study was to develop a quantitative assay to measure 
the levels of mutant and wild-type ataxin-7 in SCA7 patient-derived transformed 
lymphoblasts, with the hope that this assay could be used to test the efficacy of the 
proposed RNAi-based therapy.  Since the RNAi-effector was designed to specifically 
target the SNP linked to the expanded CAG repeat, it was necessary to develop an 
assay that was able to quantify the amount of each allele of the SNP in a given 
sample.  Therefore, two allele-specific assays were designed, one to selectively 
measure the A allele (associated with the mutant transcript), and another to 
measure the G allele (associated with the wild-type transcript). 
 
Because the aim of the assay was to quantify the levels of mRNA transcript, it was 
necessary to use cDNA, rather than genomic DNA, as the template for further PCR-
based assays.  Total RNA can be isolated from cells and used for downstream 
assays, however, the single-stranded nature of RNA and the high prevalence of 
RNases (enzymes which degrade RNA) means that RNA in its native form is highly 
unstable, and cannot be stored for extended periods of time.  Therefore, reverse 
transcription enzymes (RNA-dependent DNA polymerases isolated from 
retroviruses) are used to synthesize complementary DNA (cDNA) from mRNA, 
which can be stored over extended periods of time and used in the same way as 
genomic DNA, but with the same nucleotide sequence as the mRNA transcript from 
which it was derived.    
 
2.5.1 Tissue culture methods 
Whole blood samples had previously been obtained from four SCA7 patients, 
hereafter referred to as CA65.3, CA65.4, CA65.5 (3 individuals from the same 
family), and CA165.2.  In addition, numerous de-identified control samples were 
obtained from individuals unaffected with SCA7.  Ten millilitres of whole blood was 
collected in a heparinised collection tube.  B-lymphocytes within each sample were 
isolated and transformed using Epstein-Barr virus (EBV) in order to immortalise 
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over a long period of time.  Once the cells are transformed, they can be frozen and 
stored in liquid nitrogen for extended periods of time, providing a continuous 
source of DNA and RNA for future studies.  Isolation and transformation of 
lymphocytes was performed by a member of the NHLS, using a method previously 
described (Freshney and Freshney, 1994).   
 
2.5.1.1 EBV preparation 
The EBV-producing marmoset B-lymphoblastoid cell line (B95-8) was cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, USA) supplemented with 
10% (v/v) Foetal Calf Serum (FCS) (Sigma-Aldrich, USA), and grown at 37°C 
supplemented with 10% CO2 until medium was well conditioned (yellow in colour).  
The conditioned medium was collected in a 50ml conical tube and centrifuged at 1 
000 rpm for 10 minutes (Sigma 302K centrifuge).  The supernatant was removed 
and filtered through a 0.22µm filter to remove donor lymphoblastoid cells.  An 
equal quantity of fresh culture medium was added and the solution was stored at 
4°C for up to 6 months. 
 
2.5.1.2 Lymphoblast isolation and transformation 
The buffy coat and plasma was isolated from a 10ml whole blood sample 
(heparinized) by centrifuging for 10 minutes at 3 000 rpm at room temperature 
(Sigma 302K centrifuge).  The buffy coat and plasma was collected using a 10ml 
pipette.  The mixture was then layered on 5ml of Lymphoprep separation medium 
(Axis-Shield, Norway) in a 50ml conical tube, followed by centrifugation at 3 500 
rpm for 20 minutes.  The lymphocytes were removed via pipette from the interface 
between the Lymphoprep and plasma, and washed three times with culture 
medium at 1 000 rpm for 10 minutes.  Thereafter cells were suspended in a conical 
tube containing 5ml of prepared EBV (see above) and transferred to a 25cm2 tissue 
culture flask with 100µl of Phytohaemagglutinin (PHA) (Invitrogen, USA) (final 
concentration 2mg/l) to inactivate regulatory T cells.    The flask was incubated 
upright at 37°C (10% CO2).  After 3 days 2.5ml of the medium was removed and 
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suspension was diluted in 2 volumes of fresh culture medium (DMEM with 10% 
FCS) and cultured at 37°C supplemented with 10% CO2. 
 
2.5.2 RNA extraction and cDNA synthesis 
Prior to RNA extraction, 1 000 000 lymphoblast cells were seeded in 5ml of DMEM.  
After further culturing for three days, RNA was extracted following the Roche High 
Pure RNA Isolation kit (Roche, Switzerland) protocol.  Following extraction, the RNA 
concentration was determined using the NanoDrop ND-1000 Spectrophotometer 
and NanoDrop 1000 software (NanoDrop Technologies, USA).  Additionally, 8µl of 
the undiluted RNA sample (approximately 800ng) was loaded onto a 1% agarose gel 
and electrophoresed at 120V to determine the integrity of the sample.  Total RNA 
should exhibit two high molecular weight bands, corresponding to 18S and 28S 
ribosomal RNA.  Each sample of RNA was diluted in distilled water to give a 
concentration of 250ng/µl, and aliquoted into 2µg samples.  Aliquots were 
subsequently stored at -80°C for later use, or used directly to synthesize cDNA 
following the Novagen First Strand cDNA synthesis kit (EMD Chemicals, USA) 
protocol, using oligo(dT) primers. 
 
For initial experiments, the concentration of the cDNA was determined using the 
NanoDrop ND-1000.  cDNA was then diluted to 100ng/µl to be used in further 
applications.  However, cDNA cannot be reliably quantified spectrophotometrically 
without further purification.  Therefore, for further experiments, cDNA was 
allocated a concentration based on the original quantity of RNA used to synthesize 
the cDNA.  For example, if 2µg of RNA was used in a 20µl cDNA synthesis reaction, 
the resulting cDNA was allocated a concentration of 100ng/µl.    
 
2.5.3 Design of allele-specific primers 
PCR primers were designed to distinguish between the two alleles of the SNP of 
interest (rs 377 4729) using methods described previously.  Various methods can be 
used to discriminate between two alleles, with the most common involving the 
incorporation of a mismatch to the SNP at the 3’ end of the forward primer, or one 
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have different reaction efficiencies, therefore it is possible to design primers that 
are able to discriminate between alleles at a specific locus, allowing specific 
amplification of the allele of choice (illustrated in Figure 5). 
 
 
Figure 5: Allele-specific primer design.  Primers matched to the DNA template at their 3’ end are extended in 
the PCR reaction (left image), whilst primers with 3’ end mismatches are not extended (right image). 
 
Based on this rationale, two or three different forward primers were designed to 
specifically amplify each of the SNP alleles, using the same PCR design principles 
described previously.  In addition, two different reverse primers were designed.  
The primer sequences are given in Table 6.  The possible primer combinations, and 
the expected PCR fragment sizes, are listed in Table 7.  Primers to amplify ataxin-7 
mRNA (regardless of genotype) were also designed and ordered from Primer Design 
(UK).  Sequences, reaction components and cycling conditions are given in Appendix 
B and C. 
 
Table 6:  Allele-specific primer sequences.  All sequences are given 5’ to 3’.  The position of SNP rs 377 4729 is 
underlined. 
Primer Sequence (5’ to 3’) 
A forward 1 (F1) CAAAGTGCCAGCCA 
A forward 2 (F2) CAAAGTGCCAGCCAT 
A forward 3 (F3) AAGTGCCAGCCATG 
G forward 1 (GF1) CAAAGTGCCAGCCG 
G forward 2 (GF2) CAAAGTGCCAGCCGT 
Reverse 1 (R1) TAGCAAGCAGTTCAGACC 
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Table 7:  Allele-specific primer combinations and expected fragment sizes 
Allele to be amplified Primer combination Expected fragment size (bp) 
A F1 and R1 376 
 F1 and R2 554 
 F2 and R1 376 
 F2 and R2 554 
 F3 and R1 376 
 F3 and R2 554 
G GF1 and R1 376 
 GF1 and R2 554 
 GF2 and R1 376 
 GF2 and R2 554 
 
 
2.5.4 Screening and optimization of allele-specific primers 
2.5.4.1 A allele-specific primers 
An initial screening was performed to determine which primer pair was most 
suitable for specific amplification of the A allele.  A total of six primer pairs were 
screened (from three forward primers and two reverse primers).  Since the primers 
would be used later in a quantitative PCR assay (qPCR), a kit designed for qPCR was 
used (SensiMix SYBR Kit, Bioline, UK), but in a standard thermocycler machine 
(MultiGene Gradient Thermal Cycler, Labnet International).  Reaction components 
and cycling conditions are given in Appendix C.  The PCR was performed on cDNA 
templates homozygous for each allele, that is, a sample with an AA genotype, and a 
sample with a GG genotype. PCR products were resolved on a 2% agarose gel (as 
described previously). The primer pair with the highest specificity for the A allele 
(with amplification of the AA sample, but not of the GG sample) was chosen for 
future experiments.   
 
2.5.4.2 G allele-specific primers 
Once the most specific primers to amplify the A allele had been identified, an 
additional two forward primers were designed, in order to amplify the G allele.  A 
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able to specifically amplify the G allele (without amplification of the A allele) being 
chosen for further experiments. 
 
2.5.5 Quantitative real-time PCR 
Quantitative PCR (qPCR), also known as real-time PCR, was first developed in 1993 
by Higuchi et al. (Higuchi et al., 1993).  The basic concept involves monitoring the 
progress of a PCR reaction over time, by measuring the fluorescence of a dye that 
binds to double-stranded DNA.  As the PCR reaction progresses, the amount of 
double-stranded DNA will increase exponentially and the fluorescence of the 
sample will increase accordingly.  SYBR Green, the intercalator dye most commonly 
used for qPCR, fluoresces as it binds to newly-synthesized double-stranded DNA.  If 
a certain threshold of detected fluorescence is set, the number of thermocycles a 
particular sample undergoes until it reaches the specified threshold is directly 
linked to the amount of starting template.  For example, a sample with a high 
abundance of a given transcript will take fewer cycles to reach the threshold, than 
another sample with a lower level of the same transcript.  The cycle at which the 
sample reaches the fluorescence threshold is referred to as the Ct (threshold cycle).  
Therefore qPCR is a method often employed to quantify the amount of template in 
a given sample.  Since cDNA is double stranded, this method can also be used to 
quantify the amount of an RNA transcript in a sample. 
 
Once primer screening had been completed on a conventional thermocycler, the 
qPCR reactions were performed on the Rotor-Gene 6000 Real-time rotary analyzer 
(Corbett Life Science, Australia).  The Rotor-Gene differs from conventional 
thermocyclers by containing light-emitting diode (LED) and a photomuliplier  
detector.  As each sample moves past the LED, light passes through the sample, and 
the fluorescence is measured by the detector.  Therefore the amount of 
fluorescence in each sample is measured for each cycle. 
 
Further optimization was required to obtain allele-specific amplification on the 
Rotor-Gene 6000.  For the purposes of optimization, samples of each of the three 
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primers, the aim was to obtain ample amplification of the AA template, with less 
amplification of the GA template (since it would contain half the amount of the A 
allele transcript), and no amplification of the GG template.  Likewise for the G 
allele-specific primers, where amplification of the GG template was required, with 
no amplification of the AA template.  A number of parameters were changed in 
order to achieve adequate allele-specific amplification.  These included:  the 
concentration of primer added, the total volume of the reaction, the number of 
temperature steps in a cycle (two steps or three steps), the amount of cDNA added 
to the reaction, and the number of completed cycles.  The optimized reaction 
components and cycling conditions for each primer pair are given in Appendix C. 
 
2.5.6 Reference  gene 
The amount of RNA in a particular sample can be influenced by a number of factors.  
These can include the number of cells in the extraction, the RNA extraction 
efficiency, and the efficiency of the cDNA synthesis reaction.  Therefore, in order to 
make comparisons between multiple samples, one must be able to control for the 
amount of RNA in each sample.  This is most commonly achieved by quantifying the 
levels of an internal control gene (also called a reference gene).  Ideally, the 
reference gene should be ubiquitously expressed over multiple cell types, and its 
expression should be unaffected by the experimental conditions.  Once a reference 
gene is chosen, the abundance of the transcript of interest can be measured 
relative to the abundance of the reference gene. 
 
For the purposes of this study, the β-actin gene was chosen as the reference gene.  
Our collaborators at the University of Oxford (UK) performed a screening 
experiment using the geNorm Reference Gene Selection kit (Primer Design, UK).  
This kit can be used to identify the best candidate reference gene for any particular 
experimental scenario.  The expression of six candidate reference genes was 
measured over a series of experimental conditions (such as pre- and post-ataxin 7 
knockdown), and the most stable gene (identified as β-actin) was chosen as the 
reference gene for future experiments.  Primers designed to amplify the β-actin 
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components and cycling conditions used to amplify the β-actin transcript are given 
in Appendix C. 
   
2.5.7 Standard curves 
Two categories of mRNA quantification can be achieved through qPCR.  Absolute 
quantification can allow the user to measure the input copy number of a particular 
mRNA transcript in a sample.  Relative quantification is used to describe the change 
in expression of a particular transcript relative to another sample (usually an 
untreated control, or a sample at time zero in a time course experiment).  For the 
purposes of this study, the relative quantification method of analysis was used, 
since the change in expression of each transcript (A or G allele) would be measured 
before and after administration of the RNAi effector. 
 
In order to use the relative standard curve method of analysis, a dilution series 
(containing control cDNA of known concentrations) was prepared (40, 20, 10, 5, 2.5, 
1.25 ng/µl), and used in qPCR reactions with each primer pair. These samples were 
used to prepare standard curves for each test gene (each primer pair), by plotting 
the log of the concentration of each sample (x-axis) versus the corresponding Ct 
value (y-axis).  The equations of the resulting straight line graphs were obtained, to 
be used for analysis of the test samples. 
 
2.5.8 Data analysis 
Ct values for each sample were attained using the Rotor-Gene 6000 series software 
(Corbett Research, Australia).  In order to calculate the concentration of cDNA in 
each unknown sample (test samples), the experimentally obtained Ct value was 
used in the equation acquired from the standard curve previously prepared for the 
gene of interest.  This value could then be normalised to the β-actin value obtained 
for the same sample (as the endogenous control), to account for different amounts 
of starting material.  These values could then be used for downstream analyses.  A 
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Figure 6: Schematic diagram illustrating the analysis of qPCR data 
 
  
Obtain Ct value for each sample using 
Rotor-Gene software.
Use Ct value in equation from standard 
curve, to calculate input value.
Normalise input value for test gene to 
the appropriate β-actin input value.
Compare expression levels of test 
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2.5.9 Experiment 1 
2.5.9.1 Aim 
To confirm specificity and sensitivity of the optimized allele-specific qPCR assay in 




Since all three genotypes (AA, GA and GG) were required for the experiment, the 
following patient- and control-derived cell lines were used: 
 
Table 8:  Samples used in Experiment 1 
Patient Genotype Disease status 
CA 65.3 AA Affected 
CA65.4 AA Affected 
CA 65.5 AA Affected 
CA 165.2 GA Affected 
Con 6 GA Unaffected 
Con 9 GG Unaffected 
 
2.5.9.3 Method 
One million cells from each cell line were seeded in 5ml DMEM.  RNA was extracted 
and cDNA synthesized as described previously.  Three separate extractions and 
syntheses were completed for each cell line, resulting in a, b and c samples for each 
line (e.g. CA 65.3a, CA 65.3b, CA 65.3c).  qPCR was completed on each sample as 
described previously, using the ataxin-7, β-actin, A-allele specific and G-allele 
specific primer pairs.  Each sample was measured in technical triplicate (the same 
sample measured three times), and a no template control was included, where 
distilled water is used in the place of the cDNA template. 
 
2.5.9.4 Analysis 
Resulting Ct values were used in equations obtained from the standard curves to 
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to the appropriate β-actin input value to account for differences in starting 
material.  The resulting A-allele and G-allele transcript expression values were 
plotted on bar graphs as a percentage of total ataxin-7 expression to indicate 
relative levels of each transcript in each sample.  The expression values for the 
biological triplicates were averaged and plotted, to indicate general trends in 
expression between individuals.  Thereafter the samples were grouped and 
averaged by genotype (AA, GA or GG).  This gave an indication of sensitivity of the 
assay.  For example, if the A allele-specific primers were used in qPCR reactions 
with samples of AA, GA and GG genotype, one would expect the AA sample to show 
a similar expression level as the total ataxin-7 transcript (which was measured 
regardless of phenotype).  The heterozygous samples should show approximately 
half the amount of transcript compared to total ataxin-7, and the GG samples 
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2.6 Section D: Development of a quantitative assay to measure levels 
of heat shock proteins 27 and 70 in SCA7 patient-derived 
lymphoblasts. 
Previous reports have shown reduced levels of heat shock protein 27 and 70 (Hsp27 
and 70) expression in patient-derived lymphoblasts, compared to cells derived from 
control individuals (Tsai et al., 2005).  Our aim was to validate these results in our 
cohort of patients.  Changes in expression of Hsp27 and Hsp70 between patient- 
and control-derived cells may serve as a measurable phenotype associated with the 
disease.   This may provide a useful tool for measuring the effect of knock-down of 
the mutant ataxin-7 transcript, since Hsp levels could be measured before and after 
administration of the therapy.  
 
In order to quantify the amount of each transcript in our patient samples, qPCR 
primers were designed and ordered from Primer Design (UK).  Since these primers 
had been designed and previously tested by the company, minimal optimization 
was required.  Reaction components, cycling conditions and primer sequences are 
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2.6.1 Experiment 2 
2.6.1.1 Aim 
To determine the expression levels of Hsp27 and 70 in patient- and control-derived 
lymphoblast cell lines, in order to confirm or refute previous studies reporting 
reduced expression of these transcripts in patient-derived cells. 
 
2.6.1.2 Samples 
The cell lines used for Experiment 2 (along with the individual’s disease status) are 
listed in Table 9.  A total of four patient-derived cell lines and three control-derived 
cell lines were used for analysis. 
 
Table 9: Samples used in Experiment 2 
Patient Disease status 
CA 65.3 Affected 
CA 65.4 Affected 
CA 65.5 Affected 
CA 165.2 Affected 
Con 6 Unaffected 
Con 8 Unaffected 
Con 9 Unaffected 
 
2.6.1.3 Method 
Preparation, RNA extraction and cDNA synthesis was performed as described for 
Experiment 1.  qPCR was conducted on each sample, using the β-actin, Hsp27 and 
Hsp70 primer pairs.  Each sample was measured in technical triplicate, and a no 
template control was included. 
 
2.6.1.4 Analysis 
Data was obtained, normalised and analyzed as described in Experiment 1.  The 
average expression level of biological triplicates was determined and plotted on a 
bar graph to indicate trends in expression between individuals.  Thereafter the 
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differences in expression between the two groups.  The student’s t-test was utilized 
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Chapter 3: Results and Discussion 
 
3.1 Database query and cohort selection 
The SCA patient database of the Division of Human Genetics, UCT, was interrogated 
to select patients to be used in the study.  In order to be included in the study, 
patients either had a confirmed diagnostic test for SCA7, or the results of previous 
SCA7 diagnostic testing had been inconclusive.  Furthermore, patients were only 
included in the cohort if the Division was in possession of a genomic DNA sample.  
Thirty patients were selected to be included in the study.  The samples were coded 
to maintain patient confidentiality. 
 
3.2 DNA isolation & integrity 
Once DNA stocks had been collected from the appropriate storage areas and 
diluted to a working stock of 100ng/µl, an aliquot of each sample was subjected to 
agarose gel electrophoresis in order to determine the integrity of the DNA sample.  
An example of a DNA integrity gel is given below in Figure 7.   
 
 
Figure 7: Determination of genomic DNA integrity by agarose gel electrophoresis.  This is an image showing 
size-based separation of total genomic DNA on a 1% agarose gel.  Genomic DNA was separated by 
electrophoresis at 160V for approximately 30 minutes.  Visualisation was by SYBR Gold nucleic acid staining 
under UV light.  Lanes 1 to 14 show genomic DNA isolated from peripheral blood lymphocytes (whole blood).  
Lane L shows a 100bp molecular weight marker (Fermentas). 
 
In order for DNA to be used in downstream applications such as PCR, it is preferable 
that the DNA sample contains a high proportion of unfragmented DNA.  This 
increases the likelihood that the desired DNA template is present in the sample.  
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electrophoresed through an agarose gel, whilst DNA samples of poor integrity that 
are highly fragmented are often visible as smears or low molecular weight bands.  
The majority of DNA samples selected for the study exhibited bands of a high 
molecular weight (such as in lanes 7 and 12 in Figure 7).  In cases where the sample 
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3.3 Section A: Determination of CAG repeat size in SCA7 patients 
The first part of Objective A was to identify all SCA7 patients in the Division of 
Human Genetics database and determine their CAG repeat sizes.  Since the 
discovery of the ataxin-7 gene by David et al. in 1997, the standard method of 
diagnosis of SCA7 has been by sizing of the CAG repeat within exon 3 of the gene.  
Although original methods utilized estimations of repeat sizing by PCR and agarose 
gel electrophoresis, the development of capillary electrophoresis has allowed for 
more accurate measurements in recent years.  However, discrepancies between 
apparatus, PCR primers and methods of analysis employed by different users may 
lead to inconsistencies in accurate repeat sizing.  In the first instance, as previously 
mentioned, the accurate repeat size of an individual is required to determine 
whether either allele lies within the pathogenic range (i.e. more than 38 repeats in 
the mutant allele).  Additionally, repeat sizing may have important implications for 
individuals who do not have alleles within the pathogenic range, but within the 
intermediate range (19-37 repeats).  Whilst these individuals do not present 
clinically with SCA7, they carry a higher risk for transmitting alleles within the 
pathogenic range to their offspring, a reality that should be considered from a 
genetic counselling and family planning perspective.  
 
3.3.1 PCR optimization 
Following the design of PCR primers to amplify the region of choice (flanking the 
CAG repeat in exon 3 of ataxin-7), the first step in the PCR optimization procedure 
was to perform a temperature gradient assay in order to determine the optimal 
annealing temperature for the PCR reaction.  In this assay, twelve PCR reactions 
were prepared and each subjected to a different annealing temperature during the 
PCR reaction.  An example of the results of such a temperature gradient assay is 
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Figure 8: PCR optimization - temperature gradient.  This is an image of size-based separation of the CAG 
repeat PCR fragments on a 3% agarose gel.  PCR products were run at 160V for 40 minutes.  PCR fragments 
were visualised by SYBR Gold nucleic acid staining under UV light.  The expected size of the PCR fragment was 
292bp.  Lane L shows 100bp molecular weight marker (Fermentas).  Lanes 1 to 12 show PCR fragments 
obtained from reactions using annealing temperatures ranging from 47°C (lane 1) to 58°C (lane 12).  Lane 13 
contained a water control sample (no DNA). 
 
From the agarose gel represented in Figure 8 it was seen that the expected PCR 
product with a size of 292bp was present at all 12 temperatures, however, a large 
number of non-specific products accompanied the fragment in all cases.  Although 
the non-specific PCR products diminished with increasing annealing temperature 
(lanes 1 to 9), an increase in annealing temperature also resulted in a reduction of 
the desired PCR product (lanes 8 to 12).  Therefore further optimization was 
necessary in order to increase the specificity of the reaction.  An annealing 
temperature of 54°C was used for the rest of the optimization procedures 
(corresponding to lane 8 in Figure 8).  The Roche optimization kit was utilized to 
determine the optimal pH value and MgCl2 concentration for the reaction.  For this 
assay, 16 PCR reactions were prepared using buffers of varying pH values and 
magnesium chloride (MgCl2) concentrations.  The results of this optimization 
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Figure 9: pH and MgCl2 optimization.  This is an image of the size-based separation of the CAG repeat PCR 
fragments on a 3% agarose gel.  DNA fragments were visualised using SYBR Gold nucleic acid staining under 
UV light.  Lane L shows a 100bp molecular weight marker (Fermentas).  Lanes 1 to 16 show 16 reactions using 
buffers of varying pH values (pH 8.3, 8.6, 8.9 and 9.2) and MgCl2 concentrations (1, 1.5, 2 and 2.5 mM). 
 
It was evident from Figure 9 that none of the 16 reactions provided the optimal 
conditions for specific amplification.  No amplification resulted from reactions 
containing buffers of low MgCl2 concentrations (1mM), and increasing the MgCl2 
concentration resulted in more non-specific amplification.  An increase in pH 
similarly had little effect.  Therefore a DMSO gradient was performed to reduce 




Figure 10: DMSO PCR gradient.  An image showing the size-based separation of the CAG repeat PCR 
fragments on a 3% agarose gel.  Visualisation was by SYBR Gold nucleic acid staining under UV light.  Lane L 
shows a 100bp molecular weight marker (Fermentas).  Subsequent lanes show 5 PCR reactions, each 
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The results of the PCR optimization step using a DMSO gradient showed that the 
incorporation of 3 to 10% DMSO increased the specificity of the PCR reaction to a 
large extent.  Lanes 3, 6, 8 and 10 each showed the desired PCR fragment with an 
estimated size of 292bp, along with a smaller non-specific band.  In order to further 
increase the specificity of the reaction, FailSafe Buffer premix J (EPICENTRE 
Biotechnologies, USA) was used.  In addition, the annealing temperature time 
during the PCR reaction was decreased from 30 to 6 seconds, due to the GC-rich 
nature of the fragment.   
 
 
Figure 11: Optimized PCR reaction.  This is an image showing the size-based separation of the CAG repeat PCR 
fragments on a 3% agarose gel.  Visualisation was by SYBR Gold nucleic acid staining under UV light.  Lane L 
shows a 100bp molecular weight marker (Fermentas).  Lane 1 shows a water control.  Lanes 2 to 8 show PCR 
fragments from test samples.  Lane 7 contains an unaffected individual without an expanded allele. 
 
Figure 11 shows the results of the optimized CAG repeat PCR reaction.  The 
optimized CAG repeat PCR reaction was performed on seven different DNA samples 
obtained from SCA7 patients (lanes 2 to 6, and lane 8), and a single unaffected 
control individual (lane 7).  Samples from affected individuals displayed two distinct 
PCR products, corresponding to the wild-type (smaller fragment) and mutant (larger 
fragment) alleles.  However, the sample from the unaffected individual showed a 
single fragment corresponding to wild-type alleles in size.  In the diagnostic setting, 
a single PCR product can indicate that the individual is not affected with SCA7, or 
that the expanded mutant allele is beyond the limit of detection of the PCR assay 
(too large).  Single fragments visible on an agarose gel can often be resolved during 
capillary electrophoresis to display either two wild-type alleles of similar size, or a 
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3.3.2 Genotyping 
The CAG repeat PCR fragments obtained from patient DNA were subjected to 
capillary electrophoresis on the ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, USA) in order to determine the size of PCR fragments.  An example of a 
resulting electropherogram is presented in Figure 12.  The electropherogram 
showed green peaks corresponding to the PCR fragments.  Since the DNA used for 
the assay was isolated from peripheral blood lymphocytes, the instability of the 
expanded CAG repeat was observed by the multiple green peaks around 360bp 
(since different individual cells differ in their repeat size).   
 
 
Figure 12: Electropherogram from capillary electrophoresis of a CAG repeat PCR fragment from a SCA7 
patient’s DNA.  Relative fluorescence units are represented on the y-axis, and PCR fragment size in base pairs 
is represented on the x-axis.  Red peaks show the GeneScan 500 ROX size standard.  Green peaks show the 
migration of PCR fragments.  The image shows an allele without a CAG expansion with a size of 
approximately 280bp, and an allele with a CAG expansion (approximately 357bp). 
Since the PCR products were electrophoresed along with a size standard (Rox 500, 
shown by red peaks), the resulting raw data files were analysed to provide PCR 
product sizing using the GeneMapper software (Applied Biosystems, USA).  
Thereafter, the formula described previously by Dorschner et al. (2002) (Equation 
[2], page 44) was used to calculate the number of CAG repeats present in each PCR 
fragment.  The CAG repeat sizing results for all genotyped SCA7 patients is 
presented in Table 10.  Apart from individuals CA 104.3 and CA 637.5, all patient 
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repeats).  Individuals CA 104.3 and CA 637.5 were included in the study due to the 
lack of previous clinical and diagnostic information (their disease status was not 
known).  However, from these results it is evident that these individuals are not 
affected with SCA7, due to the lack of an expanded allele. 
Table 10: CAG repeat sizes of SCA7 patients 
Patient No. of CAG repeats 
(allele 1/allele 2) 
Patient No. of CAG repeats 
(allele 1/allele 2) 
CA 104.1 11/127 CA 531.1 12/72 
CA 104.2 12/43 CA 561.1 12/60 
CA 104.3 11/12  CA 580.1 13/56 
CA 15.1 12/63 CA 600.1 13/58 
CA 15.2 11/62 CA 65.1 12/53 
CA 15.3 13/50 CA 65.2 14/56 
CA 165.1 12/56 CA 65.4 12/39 
CA 165.2  7/51 CA 65.5 14/48 
CA 213.1 12/54 CA 96.1 11/111 
CA 240.1 14/68 CA 637.1 8/56 
CA 309.1 12/59 CA 637.2 8/60 
CA 355.1 14/83 CA 637.3 8/58 
CA 406.1 12/55 CA 637.4 11/61 
CA 417.1 14/51 CA 637.5 11/12 
CA 521.1 14/62 CA 637.6 11/60 
 
3.3.3 Previous sequencing experiments 
As part of a previous study within the Division of Human Genetics, the CAG repeat 
lengths of a subset of SCA7 patients had been sequenced to accurately determine 
their repeat length (Ms Fiona Baine, unpublished data).  A PCR of the CAG repeat 
region was completed on a subset of patients, and each allele (expanded and 
wildtype) was separately excised from an agarose gel, purified, and subjected to 
cycle sequencing.  Although capillary or agarose gel electrophoresis can only allow 
for approximation of the PCR product sized compared to a size standard, cycle 
sequencing can allow for a more accurate determination of the number of repeats, 
since the actual DNA sequence is known.  However, since cycle sequencing is more 
expensive than standard genotyping, and due to difficulties with sequencing of the 
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used for diagnostic purposes.  The results of the previous sequencing experiments, 
along with the genotyping results from this study, are presented below in Table 11. 
Table 11: Comparison of sequencing and genotyping results for CAG repeat sizes in SCA7 patients. 
Patient Genotyping results  
(allele 1/ allele 2) 
Sequencing results  
(allele 1/ allele 2) 
CA 96.1 11/111 10/? 
CA 165.1 12/56 10/46 
CA 355.1 14/83 12/77 
CA 417.1 14/51 12/56 
 
From the results in Table 11 there was a clear discrepancy between estimated CAG 
repeat sizes obtained from the standard genotyping and cycle sequencing methods 
in each of the four SCA7 patients.  There was an average difference of two repeats 
when comparing the wild-type allele sizes, and a difference of 5, 6 and 10 repeats 
when comparing the mutant allele sizes.  The sequencing method failed to 
determine the mutant allele repeat number in patient CA 96.1, most likely due to 
the large size of the repeat. 
In summary, a standard genotyping method employing PCR amplification and 
capillary electrophoresis has been used to estimate the repeat sizes of the SCA7 
patients within the cohort for whom genomic DNA was available.  This information 
can be used by clinicians for more effective management of the patients, since the 
rate of disease progression and severity of future symptoms can be approximated 
from the repeat sizes.  Furthermore, patients can be counselled with regard to their 
risk of transmitting the disease-associated allele to future offspring.  However, 
comparisons with previous sequencing experiments has highlighted that this 
method may not be the most accurate means of estimating repeat length, and 
alternative methods may need to be developed.  In a recent publication by the 
European Molecular Quality Genetics Network, numerous “Best Practice 
Guidelines” for the molecular genetics testing of the SCAs have been proposed.  For 
example, the group suggests that laboratories responsible for molecular genetic 
testing should annually participate in external quality assessment schemes, and 
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should be a list of published primer sequences for general use, and sequenced 
controls should be used for accurate repeat sizing (Sequeiros et al., 2010).  The 
adherence of diagnostic laboratories to these guidelines should allow for more 
accurate repeat sizing, and a higher level of uniformity between different 
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3.4 Section B: Determination of SNP genotype (rs 377 4729) in SCA7 
patients 
A PhD graduate from the Division of Human Genetics successfully identified an 
RNAi-based effector to selectively target the mutant ataxin-7 allele within the 
South African SCA7 cohort (Scholefield et al., 2009).  This was achieved by targeting 
a SNP (rs 377 4729) linked to the mutant ataxin-7 allele in 100% of cases tested to 
date.  Due to the lack of a thorough understanding of the function of the ataxin-7 
protein, the assumption was made that the wild-type protein should be maintained 
for proper cellular functioning, and therefore only patients who are heterozygous 
for the SNP may be eligible for the therapy.  To obtain a current indication of the 
potential application scope of the therapy, all previously ungenotyped samples 
were subjected to PCR amplification and restriction endonuclease digestion. 
 
3.4.1 Restriction enzyme digestion 
PCR primers flanking the region of SNP rs 377 4729 were used to amplify the 
genomic region in all SCA7 patients who had not been genotyped previously.  An 
example of gel electrophoresis of these PCR fragments is presented in Figure 13.  All 
samples showed PCR products corresponding to the expected fragment size of 248 
base pairs (lanes 2 to 8). 
 
 
Figure 13: An image showing the size-based separation of the SNP region PCR fragments on a 2% agarose gel.  
Visualisation was by SYBR Gold nucleic acid staining under UV light.  Lane L shows a 100bp molecular weight 
marker (Fermentas).  Lane 1 shows a water control (no template control).  Lanes 2 to 8 show PCR fragments 
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Restriction enzyme digestion with Hsp92II was carried out on the resulting PCR 
fragments, and products were run on a 6% polyacrylamide gel visualised with silver 
nitrate staining as shown in Figure 14.  Polyacrylamide gel electrophoresis was 
employed rather than agarose gel electrophoresis in order to resolve the two bands 
differing by 10 base pairs (153bp and 163bp).  Samples of GG genotype displayed 
bands corresponding to 168 and 80bp in size (lane 6), whereas samples of AA 
genotype showed bands corresponding to 153, 80 and 15bp (although the 15bp 
fragments could not be visualised on the gel) (lane 2).  Samples displaying bands 
corresponding to 168, 153, 80 and 15bp had a heterozygous genotype (lanes 3, 4, 5 
and 7).   
 
Figure 14: Polyacrylamide gel electrophoresis of PCR fragments subjected to restriction enzyme digestion by 
Hsp92II.  Products were run on a 6% polyacrylamide gel and visualised by silver nitrate staining.  Lane L shows 
a 100bp molecular weight marker (Fermentas).  Lane 1 shows a water control (no template control).  Lane 8 
shows an undigested PCR fragment.  The SNP genotype of each sample is indicated at the top of the lane 
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The genotypes of the SCA7 patients genotyped for this study are presented in Table 
12. 
 
Table 12: Rs 377 4729 genotypes of SCA7 patients. 
Patient SNP 377 4729 
genotype 
Patient SNP 377 4729 
genotype 
CA 213.1 AA CA 65.2 AA 
CA 309.1 AA CA 65.4 AA 
CA 355.1 AA CA 65.5 AA 
CA 406.1 GA CA 96.1 GA 
CA 417.1 AA CA 637.1 AA 
CA 521.1 AA CA 637.2 AA 
CA 531.1 GA CA 637.3 AA 
CA 561.1 GA CA 637.4 GA 
CA 580.1 AA CA 637.6 GA 
CA 600.1 AA 
   
From the total of 30 patients who had been genotyped (previously and for this 
study), 13 individuals had been found to be heterozygous for SNP 377 4729 (43%).  
The remaining 17 individuals had an AA genotype (57%). 
 
3.4.2 Direct cycle sequencing 
In some cases, direct cycle sequencing was used to genotype individual patients and 
controls, in order to validate results obtained from restriction enzyme digestion.  
Figure 15 shows an example of a chromatogram subsequent to cycle sequencing of 
the PCR product.  The chromatogram showed coloured peaks, each colour 
corresponding to a different nucleotide base.  The sequence from test samples was 
aligned to a reference sequence to determine the position and genotype of the 
SNP.  The control sample in Figure 15 had a GG genotype, indicated by the single 
black peak at position 129.  Samples of AA genotype showed a single green peak at 
the SNP position, and heterozygous samples showed overlayed green and black 
peaks.  All samples that were validated by sequencing showed the same genotype 
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Figure 15: Chromatogram subsequent to cycle sequencing to genotype SNP rs 377 4729 in a single unaffected 
control individual.  The position of the SNP is indicated by a black arrow (therefore this individual had a GG 
genotype). 
Two separate approaches may be taken to enable further patients to be eligible for 
the therapy.  Firstly, further SNPs can be included and targeted by the RNAi 
effectors.  This approach was recently evaluated by Pfister et al. (2009), who found 
a single SNP to be heterozygous in 48% of their HD cohort.  They subsequently 
developed five allele-specific siRNAs, targeting three SNPs, that could be used to 
treat three-quarters of the United States and European HD patient populations 
(Pfister et al., 2009).  Along these lines, a further SNP (rs 373 3126) within the 
ataxin-7 gene has been calculated to have a heterozygosity of 32% in the South 
African cohort (Ms Alice Foxon, Honour’s project, 2010).  Taken together, both SNPs 
could target approximately 50% of South African patients.  Since there are 
approximately 20 known coding SNPs within the ataxin-7 gene, it is likely that 
further SNPs of higher heterozygosities in the cohort may be identified in the 
future.     
 
Another issue to note is that of the broader potential of application of the therapy 
in populations outside SA.  Although no known studies have investigated whether 
the rs 377 4729 is linked to the SCA7 mutation in other populations and global 
regions, it should be noted that a family included within this study (Family CA 637) 
are of rural northern Namibian origin.  Haplotyping studies have revealed that these 
individuals share the same common haplotype with the South African population at 
the SCA7 locus (unpublished data), and two of the five affected family members are 
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scope of application of the RNAi-based therapy may be broader than previously 
anticipated, particularly on the African continent. 
 
Another point for consideration is that it may not be necessary to knock down the 
mutant ataxin-7 allele in a specific manner, and cells may be able to tolerate a 
complete aberration of expression.  Work on a rat model of Machado-Joseph 
disease (SCA3) has shown that silencing of the wild-type ataxin-3 protein does not 
aggravate pathology, and that non-allele-specific silencing of the mutant and wild-
type transcripts reduces neuropathology (Alves et al., 2010).  Similarly, HD mice 
have been shown to tolerate silencing of the wild-type huntingtin protein for up to 
four months (Boudreau et al., 2009).  However, in the absence of well characterised 
cellular models and knock-down mouse models for SCA7, the current assumption is 
that it would be beneficial to maintain expression of the wild-type ataxin-7 protein, 
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3.5 Section C:  Development of a quantitative assay to measure levels 
of wild-type and mutant ataxin-7 
The aim of objective B was to develop a method for measuring expression levels of 
mutant and wild-type ataxin-7 in transformed lymphoblast cell lines, to be used in 
the future to test the efficacy and specificity of a recently developed RNAi-based 
therapy.  In the event that this therapy reaches clinical testing stages, it is also 
anticipated that this assay could be used to test the therapy in patient-derived cells 
in vitro, before applying the therapy to the patient. 
 
A quantitative PCR assay was developed to measure expression of each allele (G or 
A) of the SNP rs 377 4729, which is known to be linked to the SCA7 mutation in the 
South African patient population.  Three forward PCR primers were designed for 
each allele, incorporating the position of the SNP at various positions of the 3’ end 
of the forward primer.  These were screened along with two possible reverse 
primers, to identify the most specific pair.  The identified primer sets were then 
used in qPCR assays to measure expression of each transcript in mRNA isolated 
from cells of each of the three genotypes.   
 
3.5.1 Screening and optimization of allele-specific primers 
In order to identify a primer pair able to specifically amplify the A allele of rs 377 
4729, a total of six primer pairs (from three forward primers and two reverse 
primers) were screened.  cDNA templates homozygous for each allele (e.g. AA and 
GG genotypes) were used.  An example of an agarose gel resulting from the 
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Figure 16: An image showing the size-based separation of PCR fragments on a 2% agarose gel for allele-
specific primer screening.  Visualisation was by SYBR Gold nucleic acid staining under UV light.  Lane L shows 
a 100bp molecular weight marker (Fermentas).  The PCR reactions represented by lanes 1 to 6 contained 
cDNA with an AA genotype, whereas the cDNA used in lanes 7 to 12 had a GG genotype.  The primer pairs 
used in each lane was as follows:  Lane 1 and 7 – primers F1 & R1, Lane 2 and 8 – F1 & R2, Lane 3 and 9 – F2 & 
R1, Lane 4 and 10 – F2 & R2, Lane 5 and 11 – F3 & R1, Lane 6 and 12 – F3 & R2.  The expected fragment sizes 
were 376bp (if reverse primer R1 was used) or 554bp (if reverse primer R2 was used).  
 
PCR fragments corresponding to the expected sizes (376bp if primer R1 was used, 
554bp if primer R2 was used) were visible for all samples containing the DNA 
template of AA genotype.  The primer combination of F3 and R2 showed the 
brightest PCR band (lane 6), whereas the primer combination of F1 and R1 resulted 
in the least amount of PCR product (lane 1).  Conversely, when the GG DNA 
template was used, primer combinations using the F1 or F3 forward primers 
resulted in undesirable amplification of the DNA template (lanes 7, 8, 11 and 12).  
Samples containing the F2 forward primer resulted in the least amount of 
amplification of the GG DNA template (lanes 9 and 10).  Since a primer pair was 
needed to specifically amplify the A allele was required, the pair that displayed the 
best amplification of the AA template with the least amount of amplification of the 
GG template was chosen for further experiments.  Therefore primers F2 and R1 
were chosen for the qPCR experiments (used in lanes 3 and 9 of Figure 16).  A 
similar screening method was employed to identify a primer pair to specifically 
amplify the G allele of rs 377 4729 (data not shown).   Primers GF1 and R1 were 
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3.5.2 Quantitative real-time PCR 
Once appropriate allele-specific primers were identified using a standard 
thermocycler PCR machine and agarose gel electrophoresis, the experiments were 
performed on the Rotor-Gene 6000 real-time rotary analyzer (Corbett Life Science, 
Australia), in order to enable accurate quantification of each transcript.  Since 
various parameters can vary between different thermocyclers, such as ramp speeds 
between cycling temperatures, it was necessary to further optimize the allele-
specific PCR assays on the qPCR thermocycler.  For these purposes, cDNA templates 
of all three genotypes were used.  Cycling parameters were changed to obtain 
adequate amplification of samples homozygous for the allele for which the primers 
were designed, with less amplification of the heterozygous samples, and little or no 
amplification of the samples homozygous for the alternative allele. 
 
3.5.3 Standard curves 
Since the relative standard curve method of analysis was utilized, standard curves 
were prepared for each PCR primer pair by using cDNA samples of known 
concentration in each qPCR assay.  These values were used to construct a standard 
curve for each primer pair, by plotting the log of the cDNA concentration versus the 
Ct value obtained for that sample.  The equations of these curves were used to 
analyse further test samples, as described in section 2.5.8.  An example of one of 
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Figure 17: An example of a standard curve used for analysis of qPCR data.  Ct values obtained for six serial 
cDNA dilutions (y-axis) were plotted against the log of each cDNA concentration (x-axis).  The equation of the 
straight line through the data points is given on the graph. 
 
The straight line of the standard curves displayed a negative slope, since dilutions 
with a higher concentration were detected earlier during the thermocycling 
process, and therefore had lower Ct values.  The input amount for each of the test 
samples could then be calculated by applying the Ct value for each sample to the 
standard curve equation. 
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3.5.4 Experiment 1 
The aim of experiment 1 was to confirm the specificity and sensitivity of the allele-
specific qPCR assays in patient- and control-derived lymphoblast cell lines of all 
three genotypes.  The assay was used to measure expression of each allele (A and 
G) in six lymphoblast cell lines (three samples of AA genotype, two samples of GA 
genotype, and a single sample of GG genotype).  The expression of total ataxin-7 
and β-actin was also measured to serve as endogenous controls. 
 
The following results show the relative expression of the A allele in each of the six 
samples, shown separately (by cell line).  All values were normalized to β-actin 
expression and plotted as a percentage of total ataxin-7 expression. 
 
 
Figure 18: Results of allele-specific qPCR using primers designed for amplification of the A allele of SNP rs 377 
4729.  Samples show expression of the A allele transcript normalised to B-actin and expressed as a 
percentage of total ataxin-7 expression (y-axis) in six cell lines (x-axis).  Genotypes of cell lines are given in 
brackets. Individual values are shown within each column.  Error bars show standard error of the mean 
(SEM). 
 
Two distinct parameters were measured in this assay.  Firstly, the specificity of the 
assay could be evaluated by the ability of the assay to distinguish between the 
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Secondly, sensitivity could be assessed by the ability of the assay to accurately 
measure the transcript for which it was designed.  Since the primers used in this 
assay were designed to preferentially amplify the A allele transcript, it was 
hypothesised that samples of AA genotype (shown with blue bars in Figure 18) 
would show 100% of total ataxin-7 expression, since all ataxin-7 transcripts present 
would contain the A allele.  The results from Figure 18 showed a range of 
percentages from 82% (sample 65.3) to 115% (sample 65.5), with an average of 
103%.  Although these values are close to the expected value of 100%, the 
difference in values between the three cell lines suggest that the assay may not be 
particularly sensitive.  Furthermore, heterozygous cell lines (green bars) showed 
expression values of 43% and 27% of total ataxin-7 expression, once again 
indicating an insufficient sensitivity, since the expected value was 50%.  However, 
the GG sample (red bar) showed minimal expression (1%), suggesting that the assay 
could successfully distinguish between the two alleles, and preferentially amplify 
the A allele but not the G allele. 
 
Figure 19 shows the results obtained rom a similar assay, where primers designed 
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  Figure 19:  Results of allele-specific qPCR using primers designed for amplification of the G allele of SNP rs 
377 4729.  Samples show expression of the G allele transcript normalised to B-actin and expressed as a 
percentage of total ataxin-7 expression (y-axis) in six cell lines (x-axis).  Genotypes of cell lines are given in 
brackets. Individual values are shown within each column.  Error bars show SEM. 
 
Results of the G allele-specific assay showed detected expression of the G allele at 
63% of the total ataxin-7 expression in the cell line of GG genotype (red bar), as 
opposed to the expected value of 100%.  Similarly, heterozygous cell lines (green 
bars) showed expression values of 30% and 20% (the expected value was 50%).  
Together these results suggested that the G allele-specific assay was not completely 
sensitive towards changes in levels of the transcript for which it was designed.  
However, there was no non-specific detection of expression in cell lines of AA 
genotype (65.3, 65.4 and 65.5), implying that the assay was specific towards the G 
allele transcript. 
 
Altogether, the results represented in Figure 18 and Figure 19 show that two allele-
specific assays have been developed to specifically measure either the A allele or G 
allele transcript of ataxin-7 within cell lines of any genotype.  However, these assays 
may not have the accurate sensitivities towards changes in expression levels of the 
transcripts for which they were designed.  Nevertheless, they may still be used in 
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mutant ataxin-7 transcript (A allele transcript).  For these experiments, the 
expression of each allele would be measured in the cell line of choice before RNAi 
administration.  After application of the therapy, expression levels would be 
monitored to determine whether the A allele was selectively targeted by the RNAi 
effector (and would thus show reduced expression), with minimal effect on the G 
allele. 
 
The incorporation of a single mismatch into a PCR primer is the simplest method of 
allele-specific PCR detection, due to the fact that mismatched 3’ termini are 
extended less efficiently than matched termini during PCR amplification.  Various 
other approaches may be taken to improve the specificities and sensitivities of 
allele-specific assays.  Firstly, it is possible to incorporate additional mismatches one 
or two bases upstream from the 3’ end of the primer, to further destabilize 
annealing to incorrect templates, and to increase discrimination between alleles 
(Kwok et al., 1994).  An additional potential modification is the incorporation of a 
locked nucleic acid (LNA) base at the 3’ end of the allele-specific primer (Latorra et 
al., 2003).  LNAs are nucleic acid analogues with a 2’-O, 4’-C methylene bridge 
which locks the ribose ring in a C3’-endo conformation (see Figure 20), resulting in 
complementary duplexes with RNA or DNA being entropically favoured over 
mismatched duplexes (Koshkin et al., 1998). 
 
 
Figure 20:  Molecular structure of a locked nucleic acid (LNA) residue.  A 2’-O, 4’-C methylene bridge locks the 
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A further method of generating an allele-specific PCR assay includes the addition of 
“blocker” oligonucleotides, along with conventional allele-specific primers (Morlan 
et al., 2009).  The blocker oligonucleotides aid in increasing the specificity of the 
assay, by binding to the alternative allele whilst the allele-specific primers bind to 
and amplify the allele of interest.  The blockers are modified by phosphorylation at 
the 3’ end, to prevent extension during the PCR process.  The principle of this assay, 
termed Allele-Specific Blocker PCR, is illustrated below in Figure 21.  
 
 
Figure 21:  Principle of the Allele-Specific Blocker PCR method.  A blocker oligonucleotides containing a 
phosphorylated 3’ end is designed to bind to the alternative allele, preventing amplification (top image), 
whilst an unmodified oligonucleotides binds to the allele of choice, resulting in selective amplification of a 
single allele (bottom image).  Figure adapted from Morlan et al. (2009). 
 
Apart from modifications of primers, various parameters of the PCR reaction can be 
altered to improve specificity and sensitivity.  Increased annealing temperatures, 
lower dNTP concentrations, lower primer concentrations and increased MgCl2 
concentrations have been said to enhance single nucleotide discrimination  (Kwok 
et al., 1994).  Finally, additions to the PCR reaction may aid in specificity.  Apyrase, a 
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synthesized PCR product when the reaction kinetics are fast, but degrades 
nucleotides in the event of poor reaction kinetics (Ahmadian et al., 2001).  
Therefore, extension results from matched primers, but not from mismatched 
primers.  Due to time constraints, the various potential improvements to the allele-
specific assay could not be tested in this study, although it is likely that these may 
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3.6 Section D:  Development of a quantitative assay to measure 
levels of heat shock proteins 27 and 70 in SCA7 patient-derived 
lymphoblasts. 
 
Numerous studies have explored the relationship between the heat shock proteins 
and neurodegeneration, due to their endogenous role of protecting the cell during 
periods of stress.  Therefore this group of proteins has been investigated with 
regard to their role in degeneration and protection, and as potential therapeutic 
targets.  However, little focus has been placed on the role of heat shock proteins in 
SCA7. 
 
A study by Tsai et al. (2005) found reduced expression of the Hsp27 and 70 proteins 
between two SCA7 patient lymphoblast cell lines, compared to a single control line.  
Semi-quantitative RT-PCR confirmed reduced expression of Hsp70 at the mRNA 
level, but no differences in Hsp27 expression.  Together, these results suggested 
that the alteration of Hsp70 protein expression, but not Hsp27 expression, was due 
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3.6.1 Experiment 2 
The third objective of this study was to measure the mRNA expression levels of heat 
shock proteins (Hsps) 27 and 70 in patient- and control-derived lymphoblast cell 
lines, to validate previous reports suggesting reduced levels of these transcripts in 
patient-derived lymphoblast cell lines (LCLs).  Figure 22 shows the results of the 
qPCR assay to measure Hsp27 expression in four patient-derived and three 
unaffected control-derived LCLs.  
 
 
Figure 22: qPCR results showing relative expression of the Hsp27 transcript in four patient-derived and three 
control-derived LCLs (x-axis).  Expression is shown relative to β-actin (y-axis).  Error bars show SEM.  
Statistically significant difference in expression is indicated by the p-value. 
 
The comparison of Hsp27 expression between patient- and control-derived lines 
showed a significant increase in expression in cells derived from SCA7 patients 
(p<0.05), contrary to results reported by Tsai et al., who found decreased 
expression of the Hsp27 protein in patient-derived cells, but no differences in 
mRNA levels between patients and controls when evaluated using semi-
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used by Tsai et al. (two patients and a single control), these results may be a more 
accurate representation. 
 
Hsp27 belongs to the group of small heat shock proteins, and is ubiquitously 
expressed at low levels in unstressed cells.  Expression levels increase within several 
hours of exposure to stress.  Studies have shown that Hsp27 increases the 
“chaperone capacity” of cells by acting as a substrate holder for Hsp70, and by 
keeping proteins competent for refolding (Kampinga et al., 2010).  Therefore, the 
increased expression of Hsp27 in SCA7 patient-derived cells may be due to an 
innate cellular response to mitigate pathogenesis.  Studies have shown that 
overexpression of Hsp104 and Hsp27 reduces polyglutamine-mediated toxicity in 
cell-based and mouse models of HD (Perrin et al., 2007).  Additionally, 
overexpression of Hsp27 rescues neuronal inflammation in SCA17 mice (Friedman 
et al., 2009).  It should also be noted that mutations in Hsp27 are causative in the 
development of the peripheral neuropathies in the diseases Charcot-Marie- Tooth 
disease type 2F and distal hereditary motor neuropathy type 2B (Friedman et al., 
2009). 
 
Before further conclusions with regard to the exact role of Hsp27 in SCA7 
pathogenesis or protection can be made, it would be necessary to evaluate 
expression levels in a more appropriate model of the disease.  Whilst SCA7 patient-
derived lymphoblasts are known to express the mutant and wild-type ataxin-7 
proteins, the cells are not pathologically affected.  It would be beneficial to 
measure expression levels of Hsp27 in neuronal cell lines expressing the mutant 
ataxin-7 protein, or in an appropriate SCA7 mouse model.  It may be the case that 
the increase in Hsp27 expression evident in lymphoblast lines is not seen in affected 
cell types, which would further implicate Hsp27 in a protective role.  Furthermore, 
it would be necessary to determine whether the changes in mRNA expression 
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The latter part of the objective was to measure expression levels of Hsp70 between 
patient- and control-derived LCLs.  The results from this experiment are 
represented by Figure 23. 
 
 
Figure 23:  qPCR results showing relative expression of the Hsp70 transcript in four patient-derived and three 
control-derived LCLs (y-axis).  Expression is shown relative to β-actin (y-axis).  Error bars show SEM.  
Statistically significant difference in expression is indicated by the p-value. 
The results from the Hsp70 expression assay showed a significantly decreased level 
of Hsp70 in patient-derived LCLs when compared to control-derived cells (p<0.03), 
in accordance with results published by Tsai et al.  Hsp70, a molecular chaperone 
protein, plays a pivotal role in the cell during periods of stress, and under normal 
cellular conditions.  During normal growth, Hsp70 aids in folding newly synthesized 
proteins and degrading unwanted proteins.  Under stressful conditions, Hsp70 
prevents denaturation and degradation of protein substrates (Evans et al., 2010).  
Since a common phenomenon in the polyglutamine diseases is the accumulation 
and aggregation of proteins within the cell, Hsp70 and its co-chaperones have been 
linked to these diseases.  Wacker et al. (2009) found that deletion of Hsp70 in a 
mouse model of HD lead to decreased survival, aggravated neurobehavioural and 
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bodies (Wacker et al., 2009). Furthermore, studies have shown the overexpression 
of Hsp70 reduces neurodegeneration in a mouse model of SCA1 (Cummings et al., 
2001), and a Drosophila model of SCA3 (Warrick et al., 1999).   
 
As mentioned previously, the lack of defined SCA7 animal models has hampered 
studies exploring the relationships between Hsps and disease pathogenesis.  A 
single study by Helmlinger et al. (2004), utilized a transgenic mouse model of SCA7, 
which presents with severe retinopathy, to investigate the phenotypic effect of 
overexpressing Hsp70.  Whilst overexpression of Hsp70 and its co-chaperone HDJ2 
suppressed aggregation of mutant ataxin-7 protein in transfected mammalian cells 
in vitro, it failed to prevent neuropathy and aggregate formation in the transgenic 
mouse rod photoreceptors (Helmlinger et al., 2004).  Therefore it remains to be 
shown whether reduced expression of Hsp70 in SCA7 patient-derived cells could 
contribute to pathogenesis of the disease.  Whilst our data show a significant 
decrease in Hsp70 expression between patient- and control-derived cell lines, 
further studies should aim to evaluate the expression of the Hsp70 protein.  
Furthermore, it may be beneficial to perform functional studies, to determine 
whether cells with reduced expression levels are able to mount a stress response 
comparative to control cells.  
 
In summary, a qPCR-based molecular assay has been developed and used to 
measure the expression levels of Hsp27 and Hsp70 in SCA7 patient- and unaffected 
control-derived lymphoblast cell lines.  The results of these experiments showed 
significant differences in expression of the two genes between the two groups of 
cells, providing a potentially useful measurable phenotype associated with the SCA7 
disease.  In future experiments this assay may be used to measure expression of 
Hsp27 and Hsp70 in patient-derived cells before and after administration of the 
RNAi-based therapy.  Any return of expression to “normal” levels after therapy 
administration may give an indication of amelioration of the disease-associated 
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Chapter 4:  Conclusions 
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Chapter 4:  Conclusions and future work 
In summary, this study has further characterised the South African SCA7 patient 
cohort by determining the CAG repeat length for patients for whom genomic DNA 
was available within the Division of Human Genetics during 2009 and 2010.  The 
SNP rs 377 4729 was genotyped in these patients to establish the percentage of 
SCA7 patients who may be eligible for a potential RNAi-based therapy.  Two 
quantitative PCR assays were developed and tested in patient- and control-derived 
transformed lymphoblast cell lines to selectively measure the expression of each 
allele of the ataxin-7 SNP.  Finally, qPCR was employed to measure differences in 
expression levels of the heat shock proteins 27 and 70 between patient- and 
control-derived cells.  It is anticipated that these assays will be used in future 
studies to study the specificity and phenotypic effect of the RNAi effectors, to aid 
the development of the potential therapy for South African SCA7 patients. 
 
As previously mentioned, current work into the mechanisms of SCA7 pathogenesis 
and the testing of potential therapies is hampered by the lack of appropriate 
patient material and a suitable mouse model.  Unaffected cell types, such as 
fibroblasts and lymphoblasts, can be obtained relatively easily from SCA7 patients, 
however, these cells are likely to give a limited impression of disease pathogenesis 
compared to affected cell types such as neurons and photoreceptors.  However, it 
may soon be possible to create patient-derived cells of any type, due to the recently 
developed induced pluripotent stem cell (iPSC) technology.  This technique, 
developed by Takahashi and Yamanaka in 2006, employs the use of a set of defined 
transcription factors that are able to induce reprogramming of somatic cells 
(typically fibroblast cells) to a pluripotent stem cell state.  These cells can then be 
subjected to specific conditions to “programme” them to a specific cell type of 
interest (Takahashi and Yamanaka, 2006).  The development of this method has 
significant implications for diseases such as SCA7, where fibroblasts or lymphoblasts 
can be obtained from patients through relatively non-invasive methods, and 
affected cell types (such as neurons in the case of SCA7) can be developed for 
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replace diseased cells, or to test potential therapies.  Work has already begun on 
developing iPSC lines from Friedreich Ataxia patient fibroblasts (Liu et al., 2010).  
Therefore future studies should focus on development and evaluation of this 
technology. 
 
In the diagnostic setting, further attention should be placed on developing accurate 
assays for determining the CAG repeat lengths of potential SCA7 patients, to be 
published and used routinely in laboratories worldwide.  In the South African 
context, future work should focus on determining the extent of the application of 
the potential RNAi-based therapy, by studying SCA7 patients from different 
populations, in southern Africa and worldwide. Furthermore, ataxin-7 should be 
screened for additional coding SNPs with higher heterozygosity levels in the South 
African SCA7 population.  Finally, the roles of heat shock proteins in disease 
pathogenesis should be further explored (ideally in cells that exhibit ataxin-7 
mediated pathology) to determine whether these proteins may be exploited as 
therapeutic targets.   
 
The method described in this dissertation has outlined a simple technique for 
testing allele-specific RNAi-based therapies in patient-derived lymphoblasts.  Whilst 
it can be used to bring researchers a step further towards offering a therapy to 
patients with SCA7, it may also be applied to current and future studies adopting a 
similar allele-specific approach to treat other diseases.  It is anticipated that this 
research, along with the continued development of novel technologies, will lead to 
a promising future for patients with polyglutamine diseases.      
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Appendices 
Appendix A:  Basic protocols 
DNA purification from whole blood (Gentra Puregene Genomic DNA 
Purification kit) 
900µl of red blood cell lysis solution was dispensed into a 1.5ml microcentrifuge 
tube, and 300µl of whole blood was added and mixed by inverting 10 times.  The 
tube was incubated at room temperature for 1 minute, and inverted at least once 
during the incubation.  Thereafter the sample was centrifuged for 20 seconds at 13 
000 x G to pellet the white blood cells.  The supernatant was discarded by pipetting, 
leaving approximately 10µl of the residual liquid with the pellet.  The tube was then 
vortexed to resuspend the pellet in the residual liquid.  300µl of cell lysis solution 
was subsequently added, followed by vortexing to lyse the cells.  100µl of protein 
precipitation solution was added, followed by further vortexing for 20 seconds at 
high speed.  Thereafter the sample was centrifuged for 1 minute at 13 000 x G, to 
form a pellet containing precipitated contaminating proteins.  The supernatant was 
added to 300µl of isopropanol in a clean 1.5ml tube and mixed by inversion until 
DNA was visible as threads.  The tube was then centrifuged to 1 minute at 13 000 x 
G and the supernatant discarded.  Thereafter 300µl of 70% ethanol was added and 
the tube was inverted several times to wash the DNA pellet.  This step was followed 
by centrifugation for 1 minute at 13 000 x G whereafter the supernatant was 
discarded.  The pellet was air dried for 5 minutes and resuspended in 100µl of DNA 
Hydration Solution by vortexing for 5 seconds.  Finally, the tube was incubated at 
65°C for 5 minutes to dissolve the DNA. 
 
1% (w/v) agarose gel 
1g agarose D-1 LE (Hispanger, Spain) was added to 100ml 1x TBE (see below) in a 
glass flask and heated until agarose had dissolved.  When cooled, the agarose 
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10x Tris borate buffer (TBE) 
216g Tris (B&M Scientific, South Africa), 100g Boric acid (MP Biomedicals Inc, USA) 
and 14,8g EDTA (Merck, Germany) was dissolved in 2 litres of distilled water to give 
final 10x stock concentrations of 890mM Tris, 890mM Boric acid and 20mM EDTA. 
 
Loading dye 
A 40% sucrose solution was prepared and 0.25% (v/v) Bromophenol Blue (Merck, 
Germany) was added. 
 
GeneRuler 100bp DNA Ladder Plus (Fermentas, Canada) 
Image obtained from www.fermentas.com  
 
 
6% Polyacrylamide gel 
A 50ml total volume solution was prepared from 6.7 parts 40% acrylogel 5 solution 
(VWR International Ltd, England), 1x TBE and distilled water. 200ul of 10% APS 
(Merck, Germany) and 20ul Tetramethylethylenediamine (TEMED) (BDH Laboratory 
Supplies, England) was added to 16ml of the gel mix and poured between glass 
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3µl of PCR product was added to 3µl of loading dye and subjected to 
electrophoresis of 155V for 45 minutes. 
 
Silver nitrate staining: 
A 0.1% Silver Nitrate solution (Merck, Germany) and 0.15% Formaldehyde & 1.5% 
(w/v) NaOH (Merck, Germany) solution were prepared.  The polyacrylamide gel was 
rinsed in distilled water and submerged in the silver nitrate solution for 15 minutes.  
Thereafter the gel was rinsed in distilled water and submerged in the formaldehyde 
solution for 10 minutes.  After further rinsing with distilled water the gel was placed 
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Appendix B:  Primer sequences 
Gene Primer Name Length Melting 
Temperature 
(°C) 















SCA7 SNP F 20 59 AATGAACTGCCTGTCAACTC 248 
SCA7 SNP R 20 59 GCTCACAGTCCATTTCCTAC 
Ataxin-7 Atxn qPCR F 19 66.8 GCCAGCCGTGAACAATGTC  
Atxn qPCR R 21 67.4 TTCCTCCCCGTGCTATTTTCA 
Hsp27 Hsp27 F 19 63.2 ACGAGCTGACGGTCAAGAC  
Hsp27 R 19 68.6 GGGGGCAGCGTGTATTTCC 
Hsp70 Hsp70 F 24 60.4 ATGGAATCTATAAGCAGGATCTTC  
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Appendix C:  PCR and qPCR reaction components and cycling 
conditions 
 
Table 13: CAG repeat PCR reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 4.08  
FailSafe buffer J (EPICENTRE) (2X) 5 1x 
Forward primer (20µM) 0.2 0.4µM 
Reverse primer (20µM) 0.2 0.4µM 
DNA (100ng/µl) 0.4 4ng/µl 
GoTaq DNA polymerase(Promega) (5U/µl) 0.12 0.06U/µl 
Total 10  
 
Table 14: Cycling conditions for CAG repeat PCR 
 
Cycle number 
Temperature (°C) Time Number of cycles 
1 95 5 minutes 1 
2 95 30 seconds  
30  53 6 seconds 
 72 40 seconds 
3 72 7 minutes 1 
 
Table 15: SNP rs 377 4729 PCR reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 16.9  
GoTaq Buffer (Promega) (5x) 5 1x 
dNTPs (Bioline, UK) 1  
Forward primer (20µM) 0.5 0.4µM 
Reverse primer (20µM) 0.5 0.4µM 
DNA (100ng/µl) 1 4ng/µl 
GoTaq DNA polymerase(Promega) (5U/µl) 0.1 0.02U/µl 
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Table 16: Cycling conditions for SNP rs 377 4729 PCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 5 minutes 1 
2 95 30 seconds  
30  61 30 seconds 
 72 40 seconds 
3 72 7 minutes 1 
 
The 248bp PCR products were resolved on a 2% agarose gel as described previously. 
 
Table 17: Ataxin-7 qPCR reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 3.6  
SensiMix SYBR (2x) 5 1x 
Forward primer (10µM) 0.2 0.2µM 
Reverse primer (10µM) 0.2 0.2µM 
cDNA (15ng/µl) 1 2ng/µl 
Total 10  
 
Table 18: Cycling conditions for Ataxin-7 qPCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  60 30 seconds 
 72 15 seconds 
 
Table 19: A allele-specific PCR reaction components (for primer screening).  Stock solution concentrations are 
in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 9.5  
SensiMix SYBR (2x) 12.5 1x 
Forward primer (10µM) 1 0.4µM 
Reverse primer (10µM) 1 0.4µM 
cDNA (100ng/µl) 1 4ng/µl 
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Table 20: Cycling conditions for A allele-specific PCR (primer screening) 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  61 30 seconds 
 72 40 seconds 
 
Table 21: Optimized A allele-specific qPCR reaction components.  Stock solution concentrations are in 
brackets. 
Reagent Volume (µl) Final Concentration 
dH20 3.4  
SensiMix SYBR (2x) 5 1x 
Primer F2 (10µM) 0.3 0.3µM 
Primer R1 (10µM) 0.3 0.3µM 
cDNA (15ng/µl) 1 2ng/µl 
Total 10  
 
Table 22: Optimized cycling conditions for A allele-specific qPCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  60 60 seconds 
 
Table 23: Optimized G allele-specific qPCR reaction components.  Stock solution concentrations are in 
brackets. 
Reagent Volume (µl) Final Concentration 
dH20 3.4  
SensiMix SYBR (2x) 5 1x 
Primer GF1 (10µM) 0.3 0.3µM 
Primer R1 (10µM) 0.3 0.3µM 
cDNA (15ng/µl) 1 2ng/µl 
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Table 24: Optimized cycling conditions for G allele-specific qPCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  61 30 seconds 
 72 40 seconds 
 
Table 25: β-actin qPCR reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 3.4  
SensiMix SYBR (2x) 5 1x 
Primer mix (10µM) 0.2 0.2µM 
cDNA (15ng/µl) 1 2ng/µl 
Total 10  
 
Table 26: Cycling conditions for β-actin qPCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  61 30 seconds 
 72 15 seconds 
 
Table 27: Hsp27 and Hsp70 qPCR reaction components.  Stock solution concentrations are in brackets. 
Reagent Volume (µl) Final Concentration 
dH20 3.6  
SensiMix SYBR (2x) 5 1x 
Forward primer (10µM) 0.2 0.2µM 
Reverse primer (10µM) 0.2 0.2µM 
cDNA (15ng/µl) 1 2ng/µl 
Total 10  
 
Table 28: Cycling conditions for Hsp27 and Hsp70 qPCR 
Cycle number Temperature (°C) Time Number of cycles 
1 95 10 minutes 1 
2 95 15 seconds  
35  60 30 seconds 
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Electronic resources 
 Ensembl (http://www.ensembl.org/ ) 
 IDT OligoAnalyzer web-based tool (http://eu.idtdna.com/analyzer/ 
Applications/ OligoAnalyzer/Default.aspx) 
 National Center for Biology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/) 
 Oligo Calculator programme (http://www.cnr .berkeley.edu/~zimmer/oligo 
TMcalc.html) 
 US National Institute of Health registry of clinical trials 
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